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Abstract 
Background: After myocardial infarction (MI), fibrosis and an ongoing dysregulated 
inflammatory response are associated with adverse cardiac remodeling. Fluorodeoxyglucose 
(FDG) positron emission tomography (PET) is sensitive to inflammation provided 
suppression protocols are implemented to restrict the uptake of glucose in myocytes. 
Magnetic resonance imaging can be used to determine extracellular volume, a surrogate 
measure of fibrosis. In some cases, patients present with markedly reduced flow in the setting 
of a large infarct, i.e. microvascular obstruction, restricting the delivery of FDG and contrast 
agents. To overcome this problem, a constant infusion was explored as an alternative to the 
clinical standard bolus injection. This led to three objectives: a) comparison of the constant 
infusion to the bolus injection in healthy canines, b) investigation of the potential of the 
constant infusion to discriminate post-MI tissue types, and c) determination of the efficacy of 
the suppression protocol and its effect on extracellular volume.  
Methods: All imaging was done with a hybrid PET/MRI scanner. MRI images were used to 
determine the regions of interest: remote, injured and obstructed myocardium. PET images 
were used to determine inflammation. To compare the injection strategies, five healthy 
canines were examined with all three. Subsequently, eight animals were imaged at baseline 
and days 3, 7, 14, 21, and 42 post-MI using a 60-min infusion. Lastly, seven animals were 
imaged at baseline and day 5 post-MI using a 150-min infusion. Forty minutes into the 
infusion, suppression of glucose uptake in myocytes was started. 
Results: No significant differences in terms of glucose metabolism and extracellular volume 
were seen in healthy myocardium between the three injection strategies: bolus injection, 
constant infusion and bolus followed by constant infusion, showing that a strategy involving 
the constant infusion produced similar results as to those obtained with a bolus injection. 
Following MI, a significant increase in extracellular volume was seen in remote tissue on 
days 14 and 21, suggesting an inflammatory response. During the 150-min infusion, 
suppression of myocardial glucose uptake had the unexpected result of reducing FDG uptake 
in inflammatory cells within the infarcted area. 
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Conclusion: This research showed the possibility of using a constant infusion of Gd-DTPA 
and FDG to investigate inflammation within the entire myocardium. The finding that 
suppression affected inflammatory cells highlights the need for tracers which do not rely on 
myocardial glucose suppression.  
Keywords 
Myocardial Infarction, Heart Failure, Positron Emission Tomography, Magnetic Resonance 
Imaging, Hybrid PET/MRI, Constant Infusion of Tracer 
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Summary for Lay Audience 
After a myocardial infarction, commonly referred to as heart attack, scar tissue and 
inflammation develop within the injured area. The scar tissue can be imaged with MRI and 
the inflammation with PET, provided injected contrast agents can reach the heart tissue. 
Some patients present with an area of extremely low flow within the injured region, 
unreachable with a clinically used bolus injection. A goal of my research is to test whether a 
constant infusion can be used to get the PET tracer and contrast agent into the injured region 
which is critical for imaging patient after a heart attack: if the PET tracer does not enter, there 
is no way to measure inflammation. The first experiment compared bolus injection and 
constant infusion in the normal healthy heart to establish if the results from these injection 
strategies are the same. The second experiment applied this approach in a model of 
myocardial infarction to determine if a constant infusion can measure inflammation and 
scarring in the remote, injured and obstructed regions of the heart. Lastly, since the PET 
imaging technique requires an infusion of fats to block the uptake of the PET tracer in normal 
heart tissue, the efficacy of this approach was tested.  
Methods: All imaging was done with a hybrid PET/MRI scanner. MRI images were used to 
determine the regions of interest: remote, injured and obstructed myocardium. PET images 
were used to determine inflammation. To visualize inflammation lipids were infused.  
Results: No differences were seen between constant infusion and bolus injection in healthy 
tissue. Findings from the second experiment suggested damage due to inflammation in 
remote tissue at days 14 and 21 after the heart attack. The last experiment showed that the 
suppression approach affected the injured region, suggesting that suppression measurement 
of inflammation in infarcted tissue may be underestimated. 
Conclusion: This research demonstrated the ability to use hybrid PET/MRI with a dual 
contrast agent protocol to image inflammation in the myocardium. It also showed that remote 
tissue may be damaged from a myocardial infarction and that the current approach of 
suppression, necessary for inflammation imaging, may affect inflammatory cells, hindering 
accurate quantification of inflammation.  
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Preface 
The first chapter in this thesis is adapted from a published review paper: Wilk B, Wisenberg 
G, Dharmakumar R, Thiessen JD, Goldhawk DE, Prato FS. Hybrid PET/MR Imaging in 
Myocardial Inflammation Post-Myocardial Infarction. J Nucl Cardiol 2019. 27(6):2083-
2099. This chapter sets the groundwork for the rest of the thesis in terms of what has been 
done in the field of imaging inflammation post-myocardial infarction and how current PET 
and MRI techniques can be applied to complement each other. Also outlined are tracer and 
contrast agent options to image different aspects of inflammation.  In the following chapters, 
the focus is on a combination of FDG and gadolinium-based contrast agent. The constant 
infusion technique will be investigated to optimize tracer delivery and image all regions of 
the heart rather than only the infarcted area.   
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Chapter 1  
1 Hybrid PET/MR Imaging of Myocardial Inflammation 
Post-Myocardial Infarction 
In this introductory chapter, I review the current and predict the future contributions that 
hybrid PET/MRI technology can make toward advancing our understanding of 
myocardial inflammation post-myocardial infarction. First, it is necessary to describe the 
role of inflammatory cells post-MI, then the contributions that MRI has made to this 
understanding. This is followed by explaining the contribution that PET has made. Then, 
with this background on the separate contributions that MRI and PET can and, in the 
future, could make, we introduce the technology of hybrid PET/MRI and explore how it 
has, to date, and could, in the future, further our understanding of inflammation post-MI. 
We explore the potential contributions of hybrid PET/MRI if we first treat hybrid 
PET/MRI as more than a simple combination of PET and MRI. Rather, we suggest that 
hybrid PET/MRI can be treated as a new convergent technology, where the PET aspect is 
modified to the realities of MRI and the MRI modified to the realities of PET. We 
investigate, under this convergent view of hybrid PET/MRI, biophysical explorations that 
would result in new horizons in imaging inflammation post-MI. We conclude that fruitful 
research would be the development of hybrid PET/MRI protocols including combining, 
for the first time, concurrent simultaneous injections of a PET tracer and an MRI contrast 
agent. In the research that follows (chapters 2 and 3) we first demonstrate that the novel 
acquisition protocols and novel infusion methods provide valid, quantitative results. Then 
in chapter 4, we explore this methodology to address the fundamental questions with 
respect to cardiac imaging that in the past has not, and perhaps could not, be addressed if 
a convergent approach of hybrid PET/MRI had not been used. 
1.1 Introduction 
Although early mortality in patients with acute myocardial infarction (AMI) has declined 
by 75% over the past half century1, these patients still remain at risk for late adverse 
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events and death2. Evidence suggests that infarct size3,4, extent of microvascular 
obstruction within infarcted tissue5 and extent of iron precipitation6–8 following 
hemorrhagic infarction are independent predictors of left ventricular remodeling post-
AMI, leading to heart failure. Furthermore, this remodeling is associated with additional 
effects on myocardial tissue remote from the AMI caused by an ongoing dysregulated 
pro-inflammatory process9,10. The target/substrate to be imaged in post-myocardial 
infarction is predominantly inflammatory cells responding to aseptic injury. There is also 
growing evidence that the presence of iron in the infarcted tissue following a 
hemorrhagic infarct plays a further role in modulation of inflammation6,8.  
1.1.1 Role of inflammatory cells 
After AMI, pro-inflammatory processes stabilize the region of infarction with scar tissue 
that strengthens the muscle to prevent the development of an aneurysm and reduce the 
potential for sudden death from cardiac rupture11–13. Two cellular hallmarks of this pro-
inflammatory stage include neutrophils14 (peaking within the first few hours to days post-
MI in humans and dogs) and classically-activated (M1) macrophages (peaking between 3 
and 10 days post-MI in humans and dogs)6,15–20. The population of M1 macrophages is 
primarily of myeloid origin, but may also include tissue resident macrophages within the 
myocardium and those drawn from splenic reservoirs21–24. These are the dominant 
inflammatory cell types responding to MI. The pro-inflammatory period is followed by 
an anti-inflammatory stage where the predominant cellular hallmark is the recruitment of 
alternatively-activated (M2) macrophages13. Note that M1 and M2 macrophages are a 
simplification and the picture is more complex with in-between macrophage phenotypes 
and the possibility for the polarization to change25,26. It has been suspected that 
progression to heart failure post AMI is related to a sustained pro-inflammatory 
response27,28. A sustained pro-inflammatory response may also have negative effects on 
scar stability leading to cardiac rupture29.  
Anti-inflammatory clinical trials have yielded mixed results30. If anti-inflammatory 
therapies are given too early to reduce the “healing” inflammatory response, the patients 
are at increased risk of aneurysm; if administered too late, there is an increased risk of 
negative local and remote myocardial tissue remodeling. In order to develop effective 
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therapies tailored to modify this dynamic process towards improved clinical outcomes, a 
non-invasive cardiac imaging method is required to detect the differential time course, 
post-AMI, of the inflammatory processes in three myocardial tissues: a) infarcted tissue 
with microvascular obstruction (i.e. infarcted obstructed tissue, IOT), b) infarcted tissue 
excluding the zone of microvascular obstruction (i.e. infarcted not obstructed tissue, 
INOT) and c) myocardial tissue remote from the infarcted tissue (i.e. remote tissue, RT). 
These tissues may have vastly different patterns and timing of the inflammatory response. 
However, if the appropriate therapy could be tailored for each patient early in the 
management and progression of the disease process, using noninvasive imaging to 
differentiate between neutrophils, M1 and M2 macrophages, then we could optimize 
therapy in real time, inform treatment and personalize care. 
Given their divergent effects, non-invasive imaging that distinguishes between M1 and 
M2 macrophages is critical and hence an understanding of the differences that could be 
exploited for imaging is essential. Glucose uptake in M1 macrophages is approximately 
twice that of M2 macrophages and phagocytic activity of M2 is approximately twice that 
of M131,32. Also, macrophage phenotype may be distinguished based on iron handling, as 
M1 exhibit an iron storage phenotype while M2 display an iron recycling phenotype33,34. 
Macrophages are among the few mammalian cells to express the only recognized 
mammalian iron export protein, ferroportin. Its activity is subject to regulation by the 
endocrine hormone hepcidin, produced primarily in the liver in response to pro-
inflammatory cytokines, like interleukin-6, and elevated levels of iron. Systemic 
hepcidin-ferroportin interactions induce ferroportin degradation and interrupt iron 
export35. In the dog, serum hepcidin levels rise within 4 to 6 days post-MI (unpublished 
data from the laboratory of Dr. DE Goldhawk), facilitating the production of M1 
macrophages and locally depriving the injured tissue of iron. In the canine model of 
myocardial hemorrhage, Kali et al6 suggest that elevated iron stalls macrophage 
progression from M1 to M2, consistent with the interaction of hepcidin and ferroportin. 
This in turn may delay the evolution of M2 activities needed to stabilize the scar, like 
fibroblast formation, and may also damage RT by prolonging the pro-inflammatory 
activity of M1 macrophages. 
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1.2 Magnetic Resonance Imaging (MRI) of myocardial 
inflammation 
Post-MI, MRI is an attractive modality to use due to its high spatial resolution, excellent 
soft tissue contrast, and ability to mitigate and/or measure cardiac and respiratory motion. 
1.2.1 Functional Imaging 
The capability of MRI to acquire “cine” images of wall motion throughout the cardiac 
cycle during breath holds has resulted in cardiac MRI becoming effectively the gold 
standard for the quantitation of ejection fraction, end diastolic volumes and end systolic 
volumes, all important in the definition of cardiac function with respect to progression 
towards heart failure. The imaging of left ventricle wall strain showing wall fiber tracks 
has not been as important. Although developed in the 1990s36 strain imaging has yet to 
establish itself for discriminating INOT and IOT37. The imaging of smaller cardiac 
structures such as those associated with the atria have been more difficult due to the 
thinness of the atrial wall, approaching the resolution of MRI. Developments such as 
phase contrast flow imaging, where the velocity of moving magnetic moments (flow) is 
proportional to the phase shift38, and its successor, 4D Flow,  have been helpful in 
estimating effects of valve defects on regurgitant fraction in the ventricles39. Attempts to 
apply 4D Flow to investigate effects of atrial fibrillation are in development40. 
1.2.2 “Scar imaging” 
It has been shown extensively that the distribution volume of gadolinium chelates such as 
Gd-DTPA corresponds to the extracellular space in the myocardium. This is calculated as 
the ratio of the concentration of Gd chelate in the myocardium divided by the 
concentration in the blood, which is often referred to as the partition coefficient and 
designated as λ. The volume of distribution can be calculated from λ if the hematocrit 
(Hct) is known, i.e. Vd = λ x (1 – Hct). It has been shown in both humans and dogs that λ 
in myocardial tissue post-MI increases from approximately 0.45 to 0.9 ml/g41–43. For a 
hematocrit of 0.4, this would correspond to volumes of distribution going from 0.27 to 
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0.54 ml/g. It has also been shown that a) this increase occurs within a few hours of 
occlusion/reperfusion injury43, b) that it may be reduced when the post-MI injury has 
become chronic43,44, c) it represents a marker of permanently damaged myocardium45, as 
reversible injury such as stunning41 or hibernation46 does not increase λ substantially47 
and d) given MRI’s spatial resolution, it allows the transmural extent of the infarct to be 
determined48,49. Non-contrast-enhanced scar imaging approaches have also demonstrated 
that scar following MI can be characterized on the basis of T1 mapping using modified 
Look-Locker with balanced steady state free-precession readouts at 3.0 T50,51.     
1.2.3 Edema imaging 
The T2 relaxation rate increases in tissue containing an increase in extra-cellular water 
i.e. edema, resulting in a hyperintense signal in T2-weighted MRI. The extent to which 
edema correlates with the extent of inflammation post-MI still needs to be determined52. 
1.2.4 Iron detection 
T2*-weighted cardiac MR is effective in the detection and characterization of 
infarction/reperfusion induced myocardial hemorrhage7,8,53. Histological study of canine 
myocardial infarction has shown that persistent microvascular obstruction post-MI 
culminates in the development of ferric iron oxide crystals, an increased pro-
inflammatory burden and adverse remodeling6. A postulated mechanism is that the 
conversion from M1 to M2 macrophages may be delayed by this iron crystal formation 
leading to dysregulation of the inflammatory response and progression to heart failure 
and/or an aneurysm at the site of infarction6. However, in vivo validation of this 
hypothesis requires the non-invasive differential imaging of M1 and M2 macrophages at 
the site of iron accumulation. Note that it has recently been shown in the P19 monocyte 
cell line that extracellular iron concentration (25µM of ferric nitrate) reduces ferroportin 
expression54. Quantitative susceptibility mapping (QSM) has also been used to determine 
tissue iron content and relate this to patient outcome55. 
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1.2.5 Myocardial blood flow 
Myocardial blood flow is a major consideration when discussing myocardial 
inflammation as it may play a major role in the degree and extent of the process. 
Myocardial blood flow can be measured following a bolus injection of a gadolinium 
chelate with transmural resolution56,57. However, complete heart coverage may not 
always be possible and two bolus injections to account for signal saturation are often 
employed58,59, increasing the amount of Gd-chelate that is needed though methods are 
being developed to overcome these issues. Comparison to determinations using PET have 
indicated the increased complexity of the use of Gd-chelates which have a much lower 
extraction fraction compared to PET methods such as those using 13N-Ammonia or 15O-
water60–62. It is important to note here that 13N-Ammonia enters and is trapped in living 
cells while Gd-chelates are extracellular63. 
1.2.6 BOLD MRI contrast 
Blood oxygen level dependent (BOLD) contrast in MRI has been extensively applied for 
the non-invasive study of the brain. Due to the decreased extraction fraction of oxygen 
when blood flow increases, venous blood contains higher levels of oxyhemoglobin with a 
corresponding decrease in the concentration of deoxyhemoglobin. When the venous 
deoxyhemoglobin concentration falls, then T2* increases. Hence the BOLD effect is an 
indication of the venous concentration of deoxyhemoglobin. Li et al64 have shown in 
normal volunteers that following the administration of the hyperemic agent, 
dipyridamole, with increased myocardial blood flow, there is an increase in T2* which is 
consistent with a decrease in myocardial venous deoxyhemoglobin concentration as 
myocardial oxygen supply exceeds demand64. In contrast, the administration of 
dobutamine resulted in an increase in coronary blood flow but no significant change in 
T2* consistent with a lack of change in myocardial venous deoxyhemoglobin 
concentration which is interpreted as a balance between oxygen supply and demand. This 
seminal work laid the foundation for future applications. However, not until recently has 
the BOLD measurement in the myocardium been of sufficient accuracy to be used in 
routine cardiac assessment. Recently, new MRI methods for the measurement of cardiac 
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BOLD have shown considerable promise indicating a potential to assess myocardial 
ischemia comparable with SPECT and PET methodologies65. As this has now been 
demonstrated in a canine model of ischemia, clinical studies demonstrating feasibility are 
needed. 
1.2.7 Chemical exchange saturation transfer (CEST) 
Chemical exchange saturation transfer (CEST) relies on the selective saturation and 
exchange of protons from metabolites of interest to the free protons imaged with MRI66–
68. CEST has been used to detect changes in protein concentration69, glutamate70, 
creatine71, glycosaminoglycan and most notably pH (acidoCEST)72,73 and D-glucose 
(glucoCEST)74–76 though it can be difficult to unravel changes in CEST signal from 
changes in pH, T1, temperature and other metabolites77. To our knowledge, neither 
glucoCEST nor acidoCEST have been attempted in the heart, although there would be 
some utility for alternative measurements of perfusion and pH post-MI. Cardiac CEST 
acquisitions are challenging, however, recent promising results suggest its utility for 
measuring myocardial creatine kinase78–80 and hyaluronan synthesis81 post-MI. 
1.2.8 Labeling Inflammatory Cells 
Iron particles of magnetite are strong negative contrast agents attenuating the MRI signal 
through the strong susceptibility induced by ferromagnetism. Using iron particles to label 
cells has been investigated using two different approaches. In one, inflammatory cells are 
isolated from blood lymphocytes, labeled with iron particles (such as superparamagnetic 
iron oxide (SPIO) particles) and then re-injected82. In this scenario, detection of loss of 
MRI signal within the myocardium signifies presence of labeled cells once the blood 
background is reduced, and, provided the iron particles have not been released by dying 
lymphocytes and either engulfed by other cells or lodged in the extracellular space. This 
signal may also be confounded by endogenous iron due to hemorrhage. Although it has 
been shown that, under optimal conditions, individual cells can be seen, quantitation of 
label has proven challenging due to a) the difficulty in relating the magnitude of the loss 
of MRI signal with the amount of iron particles83 and b) the dilution of the label as 
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labeled cells proliferate. This effectively limits the quantitation of the number of cells. 
Note that labeling cells with positive contrast (e.g. 19F) may overcome this issue but 
dilutions due to proliferation cannot be overcome84–86.  
In addition to phagocytic activity, monocytes and macrophages possess iron export 
activity that is detectable by MRI. In the human THP-1 monocyte cell line, iron export 
prevails regardless of extracellular iron concentration87. These cells display both 
autocrine/paracrine regulation of ferroportin as well as the endocrine response to 
hepcidin. In the multi-potent P19 cell line, extracellular iron stimulates iron export 
through transcriptional regulation, whereas the presence of hepcidin knocks it back down 
via post-translational modification35,54,88. Thus, processes governing the up and 
downregulation of iron export co-exist and contribute an MR visible signal that will be 
influenced by pro-inflammatory signaling through hepcidin, the inherent iron recycling 
activity of M2 macrophages, and the iron released from SPIO degradation.  
In the second approach, SPIO particles or perfluorocarbon agents are injected 
intravenously, hypothesizing that macrophages will engulf them and allow their 
detection. It has been shown in vitro that their engulfment rate in M2 macrophages is 
approximately 50% greater than for M1 macrophages31. However, using this method, the 
MRI signal will be related to the uptake of particles by both M1 and M2 macrophages, 
making it difficult to determine the relative contribution of each cell population to the 
signal change. 
Hyperpolarized 13C-pyruvate is another option for imaging macrophages as the lactate 
signal is increased in macrophages in vitro89. It has also been shown that rodents and pigs 
exhibit a high lactate response in the infarcted region post-MI90. 
MRI reporter genes that deliver strong contrast have been difficult to develop91. One of 
the best approaches involves introducing genes from magnetotactic bacteria in 
mammalian cells for the biosynthesis of membrane-enclosed SPIO-like particles called 
magnetosomes92. The technology was initially attempted using single gene expression 
systems93. If this technology could be implemented such that the concentration of iron 
particles in mammalian cells were equal to that in magnetotactic bacteria, theoretical 
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calculations indicate that as few as 3 cells could be detected in small animals and as few 
as 2,600 cells in large animals and humans93. This would correspond to a major 
breakthrough. For example, white blood cells from the peripheral circulation (e.g. 
monocytes) could be isolated and transfected with the MR reporter gene expression 
system, which could be programmed to produce magnetosome-like iron particles upon 
promoter activation. For example, the receptor gene could be engineered to signal, by 
production of iron particles, a molecular event involved in differentiation of the 
monocyte into an M1 macrophage. One of the main obstacles remaining is the acceptance 
of genetically modified cells for human use, although this strategy is now permitted in 
some therapeutic applications94.  
1.3 PET imaging post-myocardial infarction 
Although there are a large number of PET probes for cardiac investigation that have been 
developed, see Fig 1-1, clinical practice to date for use in post-MI patients has used only 
a few95. PET imaging post-MI is most commonly done with 18F-FDG although 
suppression of healthy myocyte glucose uptake is needed concurrent with flow tracers to 
evaluate ischemia. However, other tracers that target translocator protein (TSPO) 
receptors in inflammatory cells, such as 18F-GE180 which, while having potential for pre-
clinical small animal imaging of macrophage activity, has been largely dismissed for 
human imaging due to poor brain penetration96 or 18F-FEPPA97,98, may be used to target 
macrophages specifically.  
1.3.1 Glucose metabolism 
Inflammation can be measured with 18F-FDG due to the increased presence of glucose 
transporters on macrophages99. Due to this, uptake of glucose is upregulated in areas of 
inflammation. The non-specificity of 18F-FDG for evaluating cardiac inflammation is, 
however, compounded by uptake in normal myocytes which must be suppressed for 
successful, unambiguous detection of inflammation. The failure, at times, to effectively 
suppress that uptake by either dietary modification (high fat), overnight fasting and/or 
heparin injection, may result in failure of the test. Five percent of the time this test fails 
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even under the best diet and fasting protocols100. The reduced spatial resolution of 18F-
FDG PET compared to 3T MRI makes it difficult to uniquely identify 18F-FDG uptake in 
the three tissue regions post MI: IOT, INOT and RT. Although in vivo cardiac imaging 
reflects the significant uptake by inflammatory cells, it may not allow the distinction 
between M1 and M2 inflammatory cells. 
It has been shown in vitro that 18F-FDG uptake in M1 macrophages is greater than in M2 
macrophages. Uptake in M1 macrophage is twice that of M2 when differentiated from the 
human THP-1 monocyte cell line31. In contrast, when using primary monocytes from 
human blood, the uptake of 18F-FDG  in M1 macrophages is ten times greater than M2101. 
This is further obscured as uptake of 18F-FDG by neutrophils and monocytes may be 
similar to that of M1 macrophages. Although compartmental analysis allows the 
quantitation of glucose metabolism in units of mmol per gram per minute, there has been 
little or no attempt to evaluate quantitative 18F-FDG uptake post-MI in macrophages. The 
upregulation of 18F-FDG metabolism in inflammatory cells must be very large for this to 
be seen in infarcted tissue since the density of inflammatory cells in infarcted tissue 
would be much lower than that of myocytes in normal and remote tissue. It is unknown at 
this time if myocardial suppression of 18F-FDG uptake affects uptake of 18F-FDG in 
inflammatory cells. However, work reported of 18F-FDG studies in cardiac sarcoidosis 
indicates that if uptake is suppressed in inflammatory cells it is not sufficient to eliminate 
the strong signal of inflammation102.  
1.3.2 Blood flow 
Historically, PET myocardial blood flow measurements have used 13N-Ammonia, 15O 
water or 82Rb. At centers using PET/CT, 82Rb is often used since it does not require an 
on-site cyclotron, as opposed to 13N-Ammonia (10 min half-life) and 15O-water (2 min 
half-life). However, the 82Rb positron range reduces effective spatial resolution and, to 
date, no manufacturer of 82Rb/82Sr generators has produced an MR-compatible system. In 
this context, 13N-Ammonia is attractive for cyclotron-equipped sites and it has both high 
first pass extraction fraction and good retention characteristics103. However, the 10-
minute half-life makes stress/rest studies expensive. More development of a repeat 
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injection strategy would lower costs substantially by greatly reducing the length of the 
exam104. Alternatively, 18F-flurpiridaz is attractive due to its very high extraction and 
retention characteristics, but the cost of the tracer may negatively impact its 
implementation. Additionally, the long half-life makes it difficult to conduct stress/rest 
exams during a single imaging session as the traditional approach requires waiting for the 
tracer to have decayed between the stress and the rest scans. New single-scan dual-
injection protocols have significantly cut down the required time for Furpriridaz 
perfusion imaging105. Whereas the measurement of blood flow reserve is important in the 
scenario of stable coronary disease, its value post-MI has not been established, perhaps 
due to the difficulty of combining two 13N-Ammonia studies and one 18F-FDG study. 
1.3.3 Imaging macrophages 
Many PET ligands have been developed to detect upregulation of the mitochondrial 
translocator protein (TSPO) in activated microglia, the tissue resident macrophages of the 
brain106. Similar to FDG, TSPO is taken up more by pro-inflammatory than anti-
inflammatory cells107. There is the added limitation that a polymorphism affects TSPO 
binding108. Recently it has been shown109 in mice and humans that myocardial 
inflammation post-MI could be detected using a TSPO PET ligand. However, in vitro 
work101 suggests that this compound is taken up by other inflammatory cells besides M1 
macrophages. (It has been reported that the uptake in M1 macrophages is four times 
greater than the uptake in M2 macrophages, neutrophils, monocytes, T/NK cells and B 
cells.101) The one real advantage over 18F-FDG is that uptake of TSPO PET ligands in the 
normal myocardium does not have to be suppressed in order to detect inflammatory cells 
remote from the infarcted tissue. However, almost all research has been related to uptake 
in microglia and there is a need for more research into the in vivo uptake of TSPO PET 
ligands by inflammatory cells.  
Other targets for inflammatory tracers include the chemokine receptor CXCR4 which has 
been shown to colocalize with CD68 with the additional benefit of not being taken up by 
the myocardium. [68Ga] Pentixafor targets this receptor and has been used to image 
atherosclerosis and acute myocardial infarction110,111. Somatostatin receptor subtype-2 is 
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another promising target for PET imaging and is highly expressed in M1 macrophages. 
This can be imaged with radio-labeled DOTATATE (68Ga or 64Cu) and has been applied 
in patients with atherosclerosis112,113. Many other targets such as apoptosis114, matrix 
metalloproteinases115 or the macrophage mannose receptor (MMR) have been reported 
where MMR is upregulated in M2 macrophages116. Some of these options and others are 
summarized in figure 1-1. 
1.3.4 Injecting labeled inflammatory cells 
Although labeling white blood cells has been practiced in nuclear medicine for decades to 
detect sites of inflammation, imaging these cells within the myocardium has not been 
possible117. This is due to a) partial volume effects and b) the lack of retention of the 
tracer within the labeled cells118 . Another problem is that a bolus injection of 18F-FDG 
does not allow sufficient delivery of labeled inflammatory cells into the IOT. However, 
in animals, 111In labeled white blood cells do accumulate if injected approximately 24 
hours prior to sacrifice, as detected by  in vitro tissue sample counting119. A recently 
developed new PET probe (89Zr-DBN) that labels the (white blood) cell plasma 
membrane in a stable manner118 addresses tracer leakage. The attractiveness of a 89Zr 
label is its long half-life (3.3d) which would allow the initial high background activity in 
the left ventricular cavity to be reduced/cleared. However, effective implementation will 
require high spatial resolution anatomic images of the heart (by CT or MRI) that are 
reliably registered to the PET image to allow for effective partial volume correction and 
confidence in the location of regions of interest corresponding to IOT, INOT and RT 
identification. Although quantitation of the 89Zr signal is relatively simple and reliable 
compared to quantitation of SPIO iron particles by MRI, there is still the problem of 
quantitation of the number of cells. Obtaining the absolute number of cells rather than a 
relative amount of inflammation would be ideal for determining the efficacy of anti-
inflammatory therapy, comparison to histology or future research into the mechanism of 
inflammation post-MI. Inflammatory cell proliferation and resultant dilution of the label 
interferes with reliable quantitation. As has been shown by Blackwood et al, one likely 
advantage over MRI is that, as cells die, 89Zr-labeled debris will likely not be engulfed by 
other cells120; whereas, the SPIO particles released by labeled cells as they die have been 
13 
 
reported trapped in other cells and in the interstitium of the myocardium121,122. Reporter 
genes have also been developed for PET. Cells that are transfected and transplanted 
directly into the myocardium can be visualized after injection of the needed radiolabeled 
substrate123,124. To date, tracking intravenously-injected PET reporter gene-expressing 
cells within IOT, INOT and RT has not been accomplished and there remains the general 
prohibition of injecting genetically modified cells into humans. Nevertheless, it might be 
worth investigating if 89Zr-labeled cells could be developed that would allow 
visualization of inflammatory cells in the IOT, INOT and RT regions, if hybrid PET/MRI 
were used to identify the anatomical location of the 89Zr activity. Fig 1-1 summarizes the 
currently available PET probes and MRI agents discussed.  
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Figure 1-1: Availability of PET tracers and MRI approaches for a convergent 
hybrid PET/MRI approach to the study of cardiac inflammation post MI.  
This figure is an attempt to integrate the PET tracers and MRI approaches available for 
the study of inflammation post MI under the categories of myocyte glucose metabolism, 
detection of inflammatory cells, measurement of blood flow, examination of changes in 
the extracellular matrix (not discussed in the review) and cell death (apoptosis section). 
The intent is to suggest a synthesis of the available independent toolbox for PET and MRI 
into hybrid PET/MRI. 
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1.4 Hybrid PET/MR technology 
In Fig 1-2 the sensitivity, spatial resolution, and approximate maximum sample diameter 
of PET and MRI are compared and contrasted with other major imaging modalities 
(SPECT, CT and optical) for large animal and human imaging. It should be emphasized 
that hybrid PET/MRI is a convergence of PET and MRI and unlike PET/CT, which is a 
sequential acquisition technology, hybrid PET/MRI allows simultaneous acquisition over 
the same anatomical site. As such, although both PET and MRI are mature technologies 
when used independently, their combination with hybrid PET/MRI adds a distinct 
additional nuance that may take many years to explore and determine the value of hybrid 
PET/MRI over sequential PET and MRI.  
The engineering feat of integrating a PET ring into the bore of an MRI required a major 
redesign of whole-body PET technology125. The equipment challenges that remain 
include a) optimization of the RF/MRI receive coils to reduce the attenuation of the PET 
signal while maintaining similar performance to dedicated MRI only coils and b) MR-
based PET attenuation correction (MRAC) that compares well with CT-based PET 
attenuation correction (CTAC). However, it has been shown that artifacts and 
misalignment can impact quantitative accuracy of PET imaging by up to 6%72,126. One of 
the contributing factors is that the MRAC is often done during breath hold while PET 
data is acquired continuously. Lassen, et al, suggest that this can be corrected by taking 
µmaps at several respiratory phases or at the end of the exam127. It should also be noted 
that contrast administration could lead to misclassification of tissue128. A recent 
publication demonstrated high MR performance and low PET signal attenuation with a 
32-channel RF array designed prospectively for cardiac PET/MRI129. Furthermore, MR-
derived attenuation correction of the heart using manufacturer-provided software shows 
excellent correlation with corrections using CT125,130,131.  
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Figure 1-2: Comparison of the capability of different large animal and human 
molecular imaging modalities.  
This figure uses a log-log scale of sensitivity on the vertical axis and spatial resolution on 
the horizontal axis to demonstrate the capabilities of several imaging modalities. The 
limit on spatial resolution is shown as the left edge of each shape, while the approximate 
maximum sample size, which is dependent on both instrument design and signal 
attenuation, is shown as the right edge. The height of each shape shows the range of 
sensitivity estimates.  This figure was first published by Goldhawk et al, using data from 
several sources and is used with permission. 132–139 
 
1.4.1 Hybrid PET/MR in cardiology 
The major limitation in standalone PET (i.e. sequential PET/CT) has been the collection 
of data while the heart moves through the combined cardiac and respiratory cycles. This 
is in contrast to cardiac MRI, wherein ECG synchronization of the cardiac cycle can be 
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combined with breath hold or respiratory gating140. However, respiratory gating of PET 
results in loss of 50% of the data and dividing the cardiac cycle into eight phases results 
in a total loss of 15/16th of the collected data for each component phase. Methods have 
been developed to register cardiac MR images taken at different times in the respiratory 
cycle141,142 but to date they have not been effectively used to reduce/eliminate the effect 
of motion on the PET data without sacrificing some MRI capabilities143–146. It is possible 
that the respiratory and cardiac motion of the heart could be tracked by MRI (e.g. with 
3D navigator echoes and motion sensitive MRI acquisitions) and PET lines of response 
shifted to a fixed cardiac location (e.g. end diastole at functional residual capacity)147.  
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Figure 1-3: Longitudinal comparison of inflammation post-MI with PET/MR in a 
canine model.  
This figure shows the progression of a myocardial infarction from day 0 (top) to day 21 
(bottom). On the left are a multiplanar reconstruction of 3D T1-weighted images showing 
a 4-chamber view of the heart, acquired 20 minutes after a bolus injection of Gd-DTPA, 
in the middle is an 18F-FDG image and on the right is a combined PET/MR image. 
Myocardial glucose uptake is suppressed by lipid infusion and heparin injection. These 
images show that the areas of inflammation decrease over time. 
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Accurate registration to MRI is needed to effectively implement partial volume 
correction of cardiac PET. Although conceptually simultaneous PET/MRI over the heart 
has the needed information this has yet to be achieved. Fig 1-3 shows the importance of 
PET registration to MR to relate the extent of inflammation to the post-MI tissue types 
defined by contrast-enhanced MRI. Also, with good suppression of normal 18F-FDG 
myocyte uptake, it is only by MRI registration that the extent of 18F-FDG uptake 
associated with the different post-MI tissue types can be identified. The appeal of 
“perfect” registration is shown in Fig 1-4 where the FDG-PET and post contrast MRI 
images are perfectly registered as the data was taken after euthanasia119. Notice the 
potential for sub transmural PET signal localization. 
 
Figure 1-4: Post-mortem images of the left ventricle in a canine model. Hybrid 
PET/MRI after constant simultaneous infusion of FDG and Gd-DTPA in a large 
animal model of inflammation Post MI.  
Registration is “Perfect” as the PET/MRI were acquired post-euthanasia. Arrows 
indicate center of infarct (blue) and edges of infarct (orange). Notice that inflammation 
by PET extends beyond the infarct into the “remote” left ventricular myocardium but is 
not transmural in this “remote” region. Uptake of FDG in the “remote” myocardial 
tissue PET images could be further improved by MRI guided partial volume correction. 
Suppression of myocardial glucose uptake was achieved through lipid infusion, heparin 
injection and fasting. 
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1.4.2 Future opportunities with hybrid cardiac PET/MRI 
Without marked improved in registration between PET and MRI than what is possible 
today, the use of PET radiopharmaceuticals was dependent on low (but not zero) non-
specific binding for anatomical localization of signal. However, with automatic 
registration of the MRI image to the PET distribution, PET probes without non-specific 
binding can now be developed and used. For example, this enables the tracking of PET 
labelled cells. As outlined in the section “Injecting Labeled Inflammatory Cells”, the 
tracking of 89Zr labeled cells would be possible if hybrid PET/MRI reliably registered the 
PET and MRI images whereas this may not be reliably done with PET/CT or sequential 
PET/MR due to the lack of anatomical information from the 89Zr cells and the lack of soft 
tissue contrast of CT. 89Zr with its 3.3 day half-life is attractive for longitudinal imaging 
since it can be tracked within the body for as long as 3 weeks148. 
1.4.3 Constant Infusion Protocol 
A constant infusion approach to tracer delivery has been hypothesized to lead to an 
equilibrium concentration of the tracer and has been used for dynamic brain glucose 
metabolism measurements149,150. This has also been applied in the heart to measure 
cardiac function and glucose metabolism during hypoxia151. The constant infusion 
provides the equilibrium needed to see a change in glucose metabolism when hypoxia is 
applied. The time at which equilibrium is reached has not been quantified. Furthermore, a 
constant infusion may allow tracers to enter low-flow areas such as the IOT43. In 
combination with the previously mentioned PET/MRI techniques, a combined constant 
infusion of MRI contrast agents and PET tracers would allow for penetration of low flow 
regions such as the microvascular obstruction. 
1.4.4 Hybrid PET/MRI protocols 
An opportunity and challenge for hybrid PET/MRI is to optimize the combined PET and 
MRI protocols. One of the issues post-MI is delivery to an area of IOT. A bolus injection 
of gadolinium chelate does not penetrate IOT and hence allows its discrimination from 
the INOT. Although this lack of penetration of the MR contrast agent allows the 
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discrimination of the three post-MI tissue types, the lack of penetration of 18F-FDG 
blocks information regarding the presence or absence of inflammatory cells in the IOT. A 
bolus injection of 18F-FDG does not penetrate this zone sufficiently to give inflammatory 
cells the opportunity to sequester the tracer119. A novel and now possible approach would 
be to maintain a high blood concentration of tracer for a sufficiently long period of time 
to allow increased delivery of the tracer, even to the regions of severely compromised 
flow. This could be accomplished by a constant infusion of 18F-FDG and a Gd-chelate. If 
the Gd-chelate were able to penetrate the IOT during a 40 min infusion, then it is likely 
that 18F-FDG would also be delivered sufficiently to somewhat penetrate IOT and INOT. 
A slow infusion would allow accurate 3D T1 maps to be collected as tissue 
concentrations would not change appreciably during the acquisition and this would match 
the 3D data collection of 18F-FDG-PET. Normally 3D T1 maps cannot be accurately 
collected after a bolus injection of Gd-chelate. This would provide unprecedented 3D 
data matched in time and space between 18F-FDG-PET and Gd-chelate/MRI. As the 
concentration of Gd-chelate would not change appreciably during the 3D T1 map data 
collection, subtle changes in the extra-cellular volume could be detected in the remote 
myocardium151–153. 
One of the major differences between PET and MRI is the flexibility in binning the data 
after the acquisition. PET data can be collected in list-mode, where the location and time 
of individual PET events is recorded in a large raw data file. If physiological timing 
markers are also recorded, it is possible to reconstruct PET images at any point within the 
respiratory and cardiac phases. Hence, allowing the elimination of data corrupted by 
motion of either physiological origin and/or associated with patient bulk movement. MRI 
data is typically collected in a rigid format corresponding to a patterned projection in k-
space and MRI images are difficult to accurately reconstruct from an incomplete set of k-
space data. Recently this constraint of MRI has been addressed using a novel approach to 
randomize k-space data collection that would then allow matching in time of MRI with 
“random” PET list-mode image creation154–157. This will harmonize the way PET and 
MRI data is collected and used; which is important to fully realize the benefits of 
simultaneous acquisition such as improved PET to MRI registration.  
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Figure 1-5: Conventional vs convergent approaches to cardiac hybrid PET/MRI 
protocols.  
To date, most clinical applications of hybrid PET/MRI in cardiology have adopted 
protocols that were developed for sequential PET/MRI, which results in good PET and 
MRI images that are analyzed separately. However, good registration of PET and MRI is 
not always achieved. With an approach which treats hybrid PET/MRI as a new imaging 
modality, achieved through the convergence of the two modalities, cardiac PET/MR 
images could be achieved which are not possible with sequential acquisitions. An 
example of this potential is shown in Figure 1-4. 
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1.4.5 Hybrid PET/MRI as a convergent technology 
The convergence of PET and MRI will provide medical imaging with a new imaging 
modality. To achieve convergence there is a need for near perfect registration between 
PET and MRI as well as other factors outlined in Fig 1-5. A major limitation of PET is 
the one common signal (511 keV annihilation radiation) for all PET radioisotopes. This 
limits PET to a single radiopharmaceutical during any one data collection whereas in 
MRI there is the capacity to collect a variety of image contrasts based on different pulse 
sequences and interactions of protons with static and varying magnetic fields. For 
example, a post-MI study that requires both blood flow (e.g. 13N ammonia) and 
inflammation (e.g. 18F-FDG) by PET is difficult to achieve in a single imaging session. 
One possibility is to perform myocardial blood flow measurements using contrast-
enhanced MRI158 or BOLD MRI159 which could reduce acquisition time and dose during 
cardiac examinations, as shown in Fig 1-6. This would be especially useful in diseases 
such as cardiac sarcoidosis where it would be advantageous to study blood flow and 
inflammation102,160. Reducing the acquisition time and dose would allow investigators to 
try new studies which would presently not be possible due to the length of the scan and 
the patient’s ability to withstand it. One potential with hybrid PET/MRI is the use of the 
Tofts model161  to quantify Ktrans, a transfer constant related to tissue perfusion, during a 
constant infusion and how this relates to PET tracer dynamics162. The replacement of 
FDG-PET with glucoCEST is intriguing but issues with sensitivity of CEST and the fact 
that different glucose pools are being detected requires significant development163. CEST 
measurements sensitive to creatine kinase, hyaluronan synthesis, or pH may hold more 
promise in combination with complementary PET imaging. 
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Figure 1-6: Imaging myocardial perfusion reserve and inflammation with a 
convergent PET/MRI protocol.  
Using the current state of practice, imaging myocardial perfusion and inflammation 
sequentially would take approximately 140 minutes, unacceptably prolonging the exam. 
Using convergent technology, this could be reduced to 60 minutes with near perfect 
registration, using a rapid dual-injection for 13N-ammonia for measuring rest and stress 
blood flow, as suggested by Rust et al.104 However, when injecting the tracer beforehand 
or using alternate tracer delivery, and using BOLD MRI instead of PET164, it could be 
reduced even further, to 30 minutes or less. 
 
1.4.6 Artificial intelligence with hybrid PET/MRI 
In an extensive state-of-the-art review on artificial intelligence in cardiovascular disease, 
cardiac PET and cardiac MRI are treated separately165. The major limitation for the 
application of AI to hybrid PET/MRI for the detection of disease is the absence of a large 
cohort of “ground truth” data needed for the training sets. Some of the outcomes of AI as 
applied separately to PET and MRI suggest some applications to improve the quality of 
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information. For example, the 2016 Kuggle Data Science Bowl competition provides 
more than 1,000 cardiac cine MR data sets and the AI developed has shown that left 
ventricular end-systolic and end-diastolic volumes can be determined166. If this approach 
could be used to identify these volumes and also the epicardial and the endocardial 
borders at the same respiratory and cardiac phases as in the PET data simultaneously 
collected, then this could allow identification of the location of these cardiac structures in 
the PET images, even if in the PET images these structures were not visible. Not only 
would this automation reduce image analysis it would also allow the identification of the 
same structures in the PET data. Unfortunately, to the best of our knowledge, the needed 
PET ground truth data are not available, even for the development of machine learning 
approaches to assist in the determination of diagnostic values. It would be of considerable 
value if there were cardiac PET/CT and MRI data of the same patients even if acquired 
separately. For example, the Alzheimer’s Disease Neuroimaging Initiative archived data 
sets include brain PET and MRI images of the same patient and would allow sufficient 
training sets to develop AI for joint PET/MRI reconstructions, partial volume correction, 
MR-derived attenuation correction and dose reduction, to name a few. These findings, in 
turn, could be tested with true hybrid PET/MRI data sets. Unfortunately, there are no 
such large data sets for separate cardiac PET and cardiac MRI on the same patients. It 
seems inevitable that the data would have to be collected on hybrid PET/MRI systems to 
test joint reconstruction, kinetic modeling and partial volume correction. As we have 
suggested already, optimizing AI outcomes of combined simultaneously acquired PET 
and MRI data will require data collection protocols which are very different than what is 
collected for standalone MRI. Both supervised and unsupervised approaches should be 
explored with respect to combined connected model analysis. The number of fitted 
parameters should be small and restricted in supervised approaches whereas in the 
unsupervised approach many more parameters can be investigated165. Another example 
would be the use of MRI guided PET reconstruction to reduce radiation dose by 
constraining the PET reconstruction to reduce the effect of noise. 
A common AI approach is to try to simulate another, gold-standard modality, e.g. 
generating a pseudo CT with MRI for MRAC or predicting Gd-enhanced images with 
non-contrast MRI. Can we use this approach with matched MRI and PET to predict 
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regions of inflammation? That is, can we get enough information from multiparametric 
MRI (Gd-enhanced, blood flow, T2-weighted, T2*-weighted, and CEST) to predict 
where inflammation should be and validated with FDG-PET or TSPO-PET? 
1.5 Preclinical benchmarking using animal models 
Significant advances in cardiac imaging have often required the use of animal models 
allowing for the establishment of ground truth directly from tissue. Both small animal and 
large animal models have been effective. For example, most recently, Thackeray et al109 
used an infarct mouse model to test the use of a TSPO-PET ligand before moving to 
human studies. In contrast, large animal models, although more expensive, are needed 
since the physiology of the models better reflects the human condition and/or the imaging 
cannot be easily scaled up to humans if a small animal model were used. For example, 
most recently, Yang et al developed cardiac BOLD applications in the canine as a rodent 
model would not have been of value in developing cardiac BOLD for human 
application65. Translation of therapeutic interventions  from rodents to humans has, in 
general, had a high failure rate167. For the development of imaging biomarkers, this 
problem is exacerbated by the non-linear scaling from rodent to human imaging 
modalities92,137–139. In contrast, large animal models have a reasonable translation 
record168,169 and little or no issues with scaling of PET and MRI since studies use human 
imaging equipment. Regarding coronary artery disease and inflammation, a) infarcted 
myocardium results in an increase in the distribution volume of Gd-DTPA, characteristic 
of permanently damaged myocardium, in dogs and humans42,47,170–172 but the increase in 
the distribution volume in rats also occurs in reversibly damaged tissue173; b) the time 
course of neutrophil and macrophage activity following AMI is similar in dogs and 
humans, but different in rodents15,174–176; c) inflammatory cell response post AMI has the 
same cell markers in humans and dogs6,177; and d) the course of hemorrhage and iron 
precipitation following AMI is similar between humans and dogs. There has been some 
debate regarding the use of porcine rather than canine models for the study of the 
evolution of acute infarction. The presence of collateral vessels in the canine myocardium 
is more relevant to AMI in older humans (>50 yrs of age) while the lack of collaterals in 
pigs provides a better model for sudden death. Since progressive heart disease following 
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AMI is predominantly seen in older individuals, the canine model is superior for imaging 
inflammation post-MI178,179. 
1.6 Summary 
Standalone myocardial post-MI MRI can provide discrimination of the three tissue types: 
IOT, INOT and RT. It also can provide functional information, extent of edema and 
extent of hemorrhage. It can partially track/detect inflammatory cells if they can be 
labelled with iron particles or 19F. Standalone PET (i.e. PET/CT) can quantify 
inflammation with 18F-FDG or TSPO-targeted tracers, but not specifically with respect to 
pro-inflammatory vs. the anti-inflammatory signal and, in the case of 18F-FDG, requires 
myocardial suppression which is not always successful. A hybrid PET/MR approach 
including a contrast agent sensitive to anti-inflammatory signal may be able to separate 
the pro- and anti-inflammatory signals. Hybrid PET/MRI, even with its current state of 
non-optimal cardiac registration, provides a complementary story that will allow the 
relationship between scar formation and inflammation to be discovered as is being done 
in other cardiac conditions such as sarcoidosis102,180.  
To date, the primary use of hybrid PET/MRI is to perform combined PET and MRI 
procedures in a single procedure primarily as a tool of convenience rather than as a 
means of greater understanding of pathophysiological mechanisms. To achieve the latter, 
there are four important areas of development: that are required: a) far better registration 
than what is available today that does not significantly sacrifice the acquisition of PET 
data; b) synchronized, simultaneous acquisition of PET and MRI where MRI must have 
the same flexibility as list-mode PET c) integration of quantitative and novel MRI 
techniques such as cardiac BOLD; and d) an approach that combines the large number of 
PET probes and determinants of MRI contrast in novel synergistic ways (see Fig 1-1). 
This will not only be impactful with currently available PET probes but would make it 
possible to develop new PET probes or combined PET/MRI strategies that could 
quantitate and differentiate between the different inflammatory cell phenotypes. 
Discrimination between the pro- and anti-inflammatory processes in the three tissue types 
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post-MI will be critical for the development of inflammatory therapies and for 
implementation in the individual patient.  
1.7 Research Objectives 
In this thesis, primarily the constant infusion approach to tracer and contrast agent 
delivery will be examined. Previously, a constant infusion of PET tracers has been used 
to examine cardiac metabolism during hypoxia151 in a porcine model and a constant 
infusion of Gd-DTPA has been used to examine perfusion in a canine model with MRI 
only43. However, they have not been combined in one model or post-MI while imaging 
with PET/MRI. It has also not been determined whether the constant infusion approach 
leads to the same results of extracellular volume and glucose metabolism as a clinical 
bolus injection and whether it is safe to combine FDG and Gd-DTPA in the same syringe. 
This leads to several research objectives: 
1. Since the safety of combining Gd-DTPA and FDG in one syringe has not been 
shown, the first goal in this thesis was to show that combining these is safe since 
they will be combined to complete the following objectives.  
2. Before applying the constant infusion method in a model of myocardial infarction, 
it had to be shown at baseline that the glucose metabolism and extracellular 
volume were not significantly different. Thus, the second objective was to 
determine whether the results from a bolus injection and a constant infusion are 
the same. 
3. The third objective of this thesis was to measure glucose metabolism and 
extracellular volume post-myocardial infarction in all regions of the heart 
including RT, INOT and IOT.  
4. The fourth objective was to determine whether a long constant infusion of 150 
minutes can penetrate the IOT with both FDG and Gd-DTPA. 
5. The fifth and final objective was to determine whether the current technique to 
suppress myocardial glucose uptake of fasting, heparin injection and lipid infusion 
is effective. 
Overall, this will validate the constant infusion approach with hybrid PET/MRI and it 
may allow measurements of inflammation in the RT, INOT and IOT.  
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1.8 Thesis Outline 
1.8.1 Simultaneous measurements of myocardial glucose 
metabolism and extracellular volumes with hybrid PET/MRI 
using concurrent injections of Gd-DTPA and [18F]FDG 
In Chapter two, Simultaneous measurements of myocardial glucose metabolism and 
extracellular volumes with hybrid PET/MRI using concurrent injections of Gd-DTPA and 
[18F]FDG, the first two objectives were addressed: the safety of combining gadolinium-
based contrast agent and FDG in one syringe and comparing the results from a bolus 
injection and a constant infusion at baseline. FDG and Gd-DTPA were combined in a 
single syringe for 90 minutes and analysed for changes in pH and radiochemical purity 
and identity with radiometric thin layer chromatography. In addition to that, 6 healthy 
canines were imaged with PET/MRI with 3 different injection protocols of combined Gd-
DTPA and FDG: 60-minute constant infusion, bolus injection and bolus injection 
followed by a 30-minute constant infusion. All of these were done without suppression 
and then repeated with suppression by heparin injection and lipid infusion. Note that 
animals were fasted in either case as a requirement for anesthesia181.  
1.8.2 Tracking the progress of inflammation with PET/MRI in a 
canine model of myocardial infarction 
In chapter three, Tracking the progress of inflammation with PET/MRI in a canine model 
of myocardial infarction, the third objective, measuring glucose metabolism and 
extracellular volume over time post-MI, was addressed. Eight animals were imaged at 
baseline and on days 3, 7, 14, 21 and 43 with hybrid PET/MRI during a constant infusion 
of Gd-DTPA and FDG. Glucose metabolism and extracellular volume were measured in 
RT, INOT and IOT. The values of both are compared among days so that a timeline of 
inflammation can be established in all tissues182.   
1.8.3 Investigating the effects of myocardial glucose suppression 
on the incorporation of FDG into pro-inflammatory cells in a 
canine model of myocardial infarction 
In chapter four, Investigating the effects of myocardial glucose suppression on the 
incorporation of FDG into pro-inflammatory cells in a canine model of myocardial 
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infarction, the fourth and fifth objectives were addressed. As such, the degree of 
penetration of tracer and contrast agent into the IOT was measured and the effect of 
myocardial glucose suppression on inflammatory cells was investigated. To determine 
the impact of myocyte glucose suppression, the constant infusion was increased from 60 
min to 150 minutes in 6 animals studied at baseline and at day 5 post-MI. This allowed 
measurements of glucose metabolism without suppression to be measured in the infarcted 
tissue for the first 40 minutes of the constant infusion. This result was then compared to 
the glucose uptake in this infarcted tissue during active suppression for the period of 50 
to 90 minutes and then again after the suppression for the period from 100 to 150 
minutes. 
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Chapter 2  
2 Simultaneous measurements of myocardial glucose 
metabolism and extracellular volumes with hybrid 
PET/MRI using concurrent injections of Gd-DTPA and 
[18F]FDG 
2.1 Introduction 
Pathological alterations in myocardial tissue composition can be assessed using 
cardiovascular magnetic resonance imaging1. Absolute T1 relaxation times throughout 
the myocardium can be quantified using T1 mapping before and after administration of a 
gadolinium-based contrast agent (GBCA)2. Pre- and post-contrast T1 maps can be 
combined to give a direct measure of the extracellular volume (ECV)2,3. Myocardial 
fibrosis, a crucial component of the pathologic remodeling leading to heart failure, is 
characterized by myocardial extracellular matrix expansion and accumulation of 
interstitial collagen4. GBCA track extracellular collagen, which is the principal 
constituent of the expanded extracellular matrix and ECV mapping has shown promising 
results with respect to characterizing the extent of infiltrative and fibrotic cardiac 
diseases, such as sarcoidosis3–5. 
 
In order to quantify ECV accurately in the heart, single-slice breath hold T1 maps must 
be acquired spanning the entire heart3,6,7. For full heart coverage and artifact elimination, 
this requires acquisition during which the concentration of GBCA in the blood and tissue 
should not be changing significantly3,6,7. A bolus injection followed by a constant 
infusion of GBCA, given the correct timing and dose distribution between the bolus and 
constant infusion, achieves relatively rapid, constant blood concentrations which can be 
sustained for up to one hour3,6–8. Clinically, however, ECV is normally measured after a 
bolus injection of a GBCA (without an infusion)9, but the results may be affected by the 
constantly changing blood and perhaps resultant tissue contrast levels. However, there are 
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no studies that have investigated the effects on tracer concentrations and image data using 
only a prolonged constant infusion without a preceding bolus. An accurate and 
reproducible measurement of the distribution volume (VD) of GBCA, could lead to a 
more in-depth understanding of the pathology of both healthy and injured myocardial 
tissue.  
PET can provide additional complementary information to MRI particularly when PET 
and MRI are combined as a hybrid platform10,11. [18F]FDG PET/MRI is increasingly used 
for the detection of cellularly-mediated cardiac inflammation, particularly in sarcoidosis 
and, more recently, in myocardial infarction11,12. Using hybrid PET/MR with concurrent 
[18F]FDG and GBCA injections would reduce overall imaging time and can facilitate  
optimal registration of the PET and MRI images10,11. However, assessment of myocardial 
inflammation also requires suppression of myocyte uptake of [18F]FDG to be able to 
differentiate between physiological and pathological uptake of FDG by inflammatory 
macrophages11. Clinically, suppression of glucose is accomplished using intravenous 
heparin and a high fat diet11. Heparin is a glycosaminoglycan and therefore exerts a 
strong osmotic pressure on cells13. Joerges et al. has shown that extracellular heparin 
significantly increased the cell volume of fibroblasts in vitro13,
 potentially altering the 
intra/extracellular volume relationship. However, the effects of heparin on ECV in vivo 
remain unclear.  
This study was performed to determine if the issues identified above associated with 
differing infusion protocols and concurrent injections of GBCA and [18F]FDG while 
performing myocardial glucose suppression affect the determination of myocardial ECVs 
and glucose uptake. These were investigated in the setting of three different injection 
protocols: bolus, constant infusion only and a bolus followed by constant infusion. 
Further, to determine the chemical stability of the compounds when combining Gd-
DTPA and FDG, we used radiochromatography on a mixture of FDG and GBCA, once 
with a linear gadolinium chelator (Gd-DTPA, Magnevist, Bayer) and once with a cyclic 
chelator (gadobutrol, Gadovist, Bayer). 
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2.2 Materials and Methods 
2.2.1 Animal Preparation 
The care and treatment of the animals was in accordance with the University of Western 
Ontario Council on Animal Care (Animal Use Subcommittee) guidelines. Five healthy 
female canine subjects were imaged to compare the three different protocols for injecting 
Gd-DTPA: the standard bolus injection approach, delivery by a constant infusion over 60 
minutes without a bolus, or use of a bolus followed by a 30 minute constant infusion. The 
adult, female, bred-for-research hounds weighed 18-23 kg. Anesthesia for all procedures 
was induced using propofol and maintained with 1.5% - 2% isoflurane (Forane, Baxter). 
When required by the imaging protocol, the suppression of myocardial glucose uptake 
was induced using a continuous infusion of 20% lipid (Intralipid; Baxter Healthcare 
Corporation) at a rate of 0.25mL/min/kg over a 50-minute period as well as 2000 units of 
intravenous heparin injected 20 minutes prior to FDG/Gd-DTPA injection11. This we 
have shown is the most effective approach in canines.12 The requirement of the intralipid 
infusion may be related to the difference between the diet of dogs compared to humans. 
Note also that the effective use of heparin in humans is listed by weight14 whereas in dogs 
we simply used a fixed dose as the weight of all animals was similar i.e. 18-23 kg. 
2.2.2 PET/MRI Protocol 
All canine subjects were imaged with a Siemens Biograph mMR 3T clinical scanner. The 
animals were placed in a right lateral recumbent position and 3 electrodes were 
positioned on the chest. Gd-DTPA and [18F]FDG were injected through an intravenous 
line. The same five canine subjects were scanned on two different occasions for each of 
the three different injection protocols shown below (also on different days), once with the 
extensive protocol for suppression of glucose uptake by the myocardium and then again 
without this suppression protocol i.e. six different scanning sessions per canine (See 
figure 2-1 for sample images from 1 animal). Due to two unsuccessful experiments in the 
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bolus only work (figure 2-4b), two animals had only one bolus scan done, one of the 
suppressed, the other unsuppressed. 
 
Figure 2-1: Suppression differences based on injection type with FDG imaging. 
This figure shows the suppressed vs unsuppressed FDG images in a single animal (D1) 
with the same image intensity leveling. In this animal, clearly suppression was effective 
in bolus and constant infusion. As all animals are fasted prior to the scan, as necessitated 
by the anesthesia, it is likely that this alone may be enough to suppress myocardial 
glucose uptake in some cases as shown in this animal for the bolus + constant infusion 
case. 
As shown in figure 2-2, each canine was injected a total of 0.24mmol/kg of Gd-DTPA 
(Magnevist, Bayer Inc.) and 10.2 MBq/kg of FDG (produced in-house at the SJHC 
Cyclotron facility) for each of the three injection protocols. For the constant infusion only 
protocol, a 60-minute constant infusion (0.004mmol/kg/min of Gd-DTPA and 0.17 
MBq/min/kg FDG) was administered followed by 30 minutes of washout. During the 
bolus followed by a constant infusion, a bolus of 0.12mmol/kg Gd-DTPA and 5.1 
MBq/kg FDG followed by a 30-minute constant infusion (0.004 mmol/kg/min Gd-DTPA 
and 0.17 MBq/kg) was administered followed by an additional 30 minutes of washout.  
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Cardiac T1 maps (4-chamber view of the heart) were acquired with a modified Look-
Locker inversion recovery (MOLLI) sequence (ECG-gated, 35° flip angle, 256 x 218 
matrix size, 300 mm x 255.5 mm field-of-view, 6 mm slice thickness, 400ms repetition 
time, 1.12ms echo time) during breath hold at pre-contrast and then every 3 min after the 
concurrent injections: for a total of 60 min after the bolus and bolus plus constant 
infusion protocols and for 90 minutes following 60 min constant infusion protocol. Note 
that this included 30 min of washout after the end of the constant infusions. 
The PET data was reconstructed in 3-minute frames using a 3D Ordered Subset 
Expectation Maximization (OSEM) reconstruction (3 iterations, 21 subsets, 172 x 172 x 
127 matrix size, zoom of 2 and 4 mm Gaussian filter). Attenuation correction was 
achieved using a two-point Dixon MRI sequence and segmented into water, fat, lung and 
air with constant attenuation coefficients for each tissue. The PET voxel size was 2.09 x 
2.09 x 2.03 mm.  All PET data was acquired in list-mode for 60 minutes in the bolus-only 
protocol and bolus followed by CI and 90 minutes for the constant infusion only protocol.  
 
Figure 2-2: Injection protocol with three different injection strategies. 
Three different injection strategies of [18F]FDG /Gd-DTPA were used: a) a bolus 
injection only, b) a bolus followed by a 30-minute constant infusion (Bl + Cl), and c) a 
58 
 
60-minute constant infusion. In the imaging procedure in which glucose metabolism was 
suppressed a continuous infusion of intralipid and an intravenous heparin injection were 
administered 20 minutes prior to [18F]FDG /Gd-DTPA injection and MOLLI acquisition. 
2.2.3 Image Analysis 
Image analysis was performed using 3D Slicer (Open Source, BSD License) and 
MATLAB (Mathworks, R2019a). As shown in figure 2-3, manually drawn regions of 
interest (ROIs) in the 4-chamber view were used to identify the healthy myocardium and 
the left ventricular blood pool. Myocardial and blood T1 values pre- and post- Gd-DTPA 
administration were measured. Once the ROIs were defined, they were used as a template 
and copied to the rest of the images in the series. Manual adjustment of some images in 
the series was applied to offset changes in heart position. Edges were also avoided when 
drawing ROIs to minimize partial volume averaging from voxels at the myocardial-blood 
pool border. ECV was calculated using the following formula where hematocrit was 
assumed to be 0.4515. For the comparison of ECV using different injection types with and 
without glucose suppression, steady-state equilibrium was assumed to be reached when 
the difference in the calculated ECV between acquisitions was less than 5%, as done by 
White et al16 with the following equation: 
 𝐸𝐶𝑉 = (1 − ℎ𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡)
×
1
𝑝𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑇1 𝑚𝑦𝑜 −
1
𝑛𝑎𝑡𝑖𝑣𝑒 𝑇1 𝑚𝑦𝑜
1
𝑝𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑇1 𝑏𝑙𝑜𝑜𝑑
−
1
𝑛𝑎𝑡𝑖𝑣𝑒 𝑇1 𝑏𝑙𝑜𝑜𝑑
. 
Eq 1 
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Figure 2-3: Region of interest selection at baseline.  
Extracellular volume (ECV) measurements were calculated for three separate regions: 
two in the healthy myocardium (white ROI’s) and one ROI in the blood pool (purple 
ROI). The ECV was then averaged from the ROI’s from the healthy myocardium, using 
cardiac T1 maps acquired during breath hold at pre-contrast and then every 3 minutes 
following initial injection(s) of GBCA. 
2.2.4 Glucose Metabolism 
Using an in-house MATLAB script, the FDG concentration curves of all ROIs were fit to 
the Patlak model of graphical analysis17 using the following equation:  
 
[𝐹𝐷𝐺(𝑡)]𝑖 = 𝐾𝑖 ∫ [𝐹𝐷𝐺(𝜏)]𝑝 𝑑𝜏
𝑡
0
+ (𝑣𝑒
𝑃 + 𝑣𝑝
𝑃)[𝐹𝐷𝐺(𝑡)]𝑝, 
Eq 2 
 
where [𝐹𝐷𝐺(𝑡)]𝑖 is the concentration of [
18F]FDG in tissue i, 𝐾𝑖, the influx constant 
which is proportional to the rate of glucose metabolism in tissue i. [𝐹𝐷𝐺(𝑡)]𝑝 is the 
arterial plasma concentration input function which was the blood pool ROI, taken from 
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within the left ventricular cavity. 𝑣𝑒
𝑝
 is the equilibrium space of the extravascular 
exchangeable region and 𝑣𝑝
𝑃 the plasma space.  
The influx constant, 𝐾𝑖 is determined from the slope of 
[𝐹𝐷𝐺(𝑡)]𝑖
[𝐹𝐷𝐺(𝑡)]𝑝
 𝑣𝑠 
∫ [𝐹𝐷𝐺(𝜏)]𝑝𝑑𝜏
𝑡
0
[𝐹𝐷𝐺(𝑡)]𝑝
. This 
slope will be 𝐾𝑖 once it is constant, at t = t*, which was operationally defined to be 12 
minutes after the start of the constant infusion at which point equilibrium was achieved. 
[𝐹𝐷𝐺(𝑡)]𝑝 was determined from the blood concentration [𝐹𝐷𝐺(𝑡)]𝑏 corrected by the 
glucose plasma:whole blood ratio (P) of 1.37518 and the haematocrit (Hct) i.e. [FDG(t)]p 
= [FDG(t)]b (P/(1-Hct)). The tissue concentration was corrected for the partial volume 
effect in PET using a recovery coefficient (RC) of 0.7 determined for a 10 mm diameter 
cylinder on our PET/MRI imaging system (approximately equivalent to the thickness of 
the left ventricular wall)19,20 i.e.  
 
[𝐹𝐷𝐺(𝑡)]𝑖 =
[𝐹𝐷𝐺(𝑡)]𝑡
𝑅𝐶
−
1 − 𝑅𝐶
𝑅𝐶
[𝐹𝐷𝐺(𝑡)]𝑏 . 
Eq 3 
 
Using this method, 𝐾𝑖 was extracted for all ROIs in all studies. 
2.2.5 FDG stability under concurrent injection with GBCAs 
To a 10 mL vial of Magnevist (Gd-DTPA) or Gadovist (gadobutrol) was added 300 – 500 
MBq of [18F]FDG. The vial was stored upright at ambient temperature (20 – 22 oC). 
Samples were extracted at 15, 30, 60, and 90 min following initial mixing. These samples 
were analyzed for changes to pH (colorimetric paper test) and radiochemical purity and 
identity (radiometric thin layer chromatography or radioTLC) compared to [18F]FDG 
prior to mixing with GBCA. Both pH and radioTLC test methods were identical to 
standard testing methods for release of clinical [18F]FDG. The linear range for the 
radioTLC was 82 – 2290 kBq with a limit of detection of 1.6 kBq at the time of testing. 
An impurity with 3.3 MBq/mL concentration could reliably be detected. FDG was 
visualized on the TLC by coating with 10% H2SO4 in methanol and heating to give a 
brown spot. 
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2.2.6 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA). All data is presented as mean  standard error of the mean (SEM) except for Figure 
2-7 where mean +/- SD is used. The effect of different protocols on ECV over time were 
compared using a two-way repeated-measures analysis of variance (ANOVA) followed 
by Bonferroni multiple comparisons tests. Paired two-tailed t-tests were performed to 
compare ECV prior to and following washout for the constant infusion protocol. 
Comparison of differences in ECV and Ki associated with glucose suppression and 
injection protocol including during washout of Gd-DTPA was assessed with paired and 
unpaired two-tailed t tests. A p-value of <0.05 was considered to be statistically 
significant. Bonferroni’s method was done to correct for multiple comparisons when 
comparing multiple treatments’ means.  
2.3 Results 
2.3.1 FDG stability under concurrent injection with GBCAs 
At all timepoints, no changes were observed in pH or radiochemical purity. As shown in 
Table 1, radiochemical identity is confirmed by comparing the retention factors (distance 
analyte travels versus solvent front) between authentic FDG standard and [18F]FDG. The 
percent difference between the two retention factors was within 6.4 ± 1.7% and 6.5 ± 
3.1% when mixed with Magnevist (Gd-DTPA) and Gadovist (gadobutrol), respectively. 
This is well within the release specification of 10% and typical of day-to-day variance 
during clinical productions. 
Table 1: Chemical Stability when combining Gd-DTPA or gadobutrol and FDG 
Time after 
mixing 
(minutes) 
Retention Factor Mixed with Gd-
DTPA 
Retention Factor Mixed with 
Gadobutrol 
FDG [18F]FDG % Difference FDG [18F]FDG % Difference 
Original 0.41 0.43 3.0 0.41 0.43 3.0 
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15 0.33 0.32 4.4 0.44 0.40 9.1 
30 0.38 0.35 7.9 0.42 0.42 1.1 
60 0.36 0.38 4.9 0.43 0.39 8.2 
90 0.36 0.33 8.2 0.41 0.38 7.5 
Average 0.37 0.36 6.4 0.42 0.40 6.5 
StDev 0.03 0.04 1.7 0.01 0.02 3.1 
2.3.2 Evaluation of ECV in Healthy Myocardium with and without 
glucose suppression 
As shown in Figure 2-4, there was no significant effect of glucose suppression vs. no 
glucose suppression on the measured ECV at equilibrium irrespective of which infusion 
protocol was used (bolus-only: p=0.22; constant infusion-only: p=0.10; bolus followed 
by constant infusion: p=0.09). However, when comparing ECV with glucose suppression 
across all animals, irrespective of injection method, ECV is significantly higher with 
suppression (0.21 ± 0.02 vs 0.18 ± 0.01, corresponding to a 13% increase; p = 0.002). 
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Figure 2-4: The effect of glucose suppression on healthy non-infarcted myocardial 
ECV. 
Suppression was achieved with a continuous infusion of 20% lipid as well as intravenous 
heparin (2000 units). a) The mean ± SEM ECV for all injection types after equilibrium 
was reached. No significant differences were found using paired t-tests. The ECV with 
and without suppression following a b) bolus injection (note that there are only 4 data 
points given for suppression and no suppression as, due to experimental error, one 
animal did not have an initial unsuppressed successful experiment and one did not have a 
successful suppression study), c) Bl + CI injection and d) CI only for each individual 
canine. The ECV values used corresponded to when equilibrium was reached within the 
healthy myocardium. 
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2.3.3 Comparison of ECV in Healthy Myocardium – 
Measurements using Different Injection Types 
 When comparing the injection protocols, i.e.  a bolus, bolus followed by constant infusion, 
or a constant infusion, as shown in Figure 2-5, there was no significant difference (p = 
0.21) between protocols from minute 9 to minute 60. Minute 9 was chosen to exclude times 
when the tracer is still washing in and therefore may not be representative of the actual 
ECV. However, over time, the ECV calculated following the bolus injection slowly 
increased reaching a plateau at minute 18 (0.21 ± 0.02) with a significant difference (p = 
0.02) between minute 3 vs. minute 18.  There was no significant difference found for ECV 
using the constant infusion protocol at minute 60 when compared to any of the time points 
beyond that point, i.e. during the 30-minute post infusion washout period.  
 
Figure 2-5: The time course of changes in the measured ECV of Gd-DTPA in 
healthy myocardium in five canine subjects, with glucose suppression, measured 
every 3 minutes for up to 90 minutes after start of injection.  
Data are presented as mean ± SEM, N=5 for each injection method. All injection 
protocols ended at 60 minutes, except for the constant infusion of Gd-DTPA, which 
included an additional 30-minute washout period. No significant difference was found 
when comparing the different injection methods. 
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2.3.4 Glucose metabolism using Patlak parameter estimates 
Figure 2-6 shows the influx constant, Ki, a marker of glucose metabolism for healthy 
non-infarcted cardiac myocardium with and without glucose suppression using heparin 
and a continuous infusion of 20% lipid. There was no significant effect of glucose 
suppression on the measured Ki irrespective of which infusion protocol was used (bolus-
only: p=0.19; constant infusion-only: p=0.36; bolus followed by constant infusion: 
p=0.93).  
 
Figure 2-6: The effect of glucose suppression on healthy non-infarcted cardiac 
myocardium Ki, a marker of glucose metabolism.  
This figure shows the Ki of each individual canine with and without suppression 
following a a) bolus injection, b) Bl + CI injection and c) CI only for each individual 
canine. No significant differences were found using paired t-tests. The individual dogs 
are identified as D1 to D5 and suggests that the pattern of differences with and without 
suppression is not related to individual animals. 
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2.3.5 Change in T1 during each contrast delivery method 
As shown in figure 2-7, while values in the bolus experiment are increasing over time, in 
the bolus followed by CI, values are relatively constant between 10 and 30 minutes and in 
a constant infusion only, they are best between 40 and 60 minutes. These durations may 
also be increased by increasing the duration of the infusion as they only change when the 
infusion is terminated. It is important to point out that these timelines are for healthy 
tissue with blood flow of approximately 1 ml/min/g and they may vary in ischemic tissue, 
e.g. infarcted tissue, with reduced blood flow. 
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Figure 2-7: Changes in T1 values over time in both the myocardium and the blood.  
These are mean values +/- SD for all 5 canines in the suppressed glucose myocardium 
group. 
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2.4 Discussion 
The main findings were: (a) The suppression of myocardial uptake of [18F]FDG with 
heparin and lipid infusion may alter the determination of myocardial ECV using GBCA, 
(b) the infusion protocol used had no effect on the calculated ECV; but with the caveat of 
(c) ECV measured using a bolus of Gd-DTPA was underestimated if measured prior to 
the first 15 minutes following injection and (d) combining Gd-DTPA and FDG for 
concurrent injection for hybrid imaging  showed no changes in pH or radiochemical 
purity of [18F]FDG.  
This work demonstrates the equivalence of the determination of ECV under the different 
injection scenarios for the collection of a T1 map over a single slice when the 
concentration of GBCA did not vary significantly during the breath hold needed for 
acquisition. However, a T1-map of ECV over the entire left ventricular myocardium is 
needed if inflammatory disease is non-uniformly distributed as is most often the case e.g. 
post myocardial infraction, cardiac sarcoidosis, etc21,22. As a 3D T1 map would require 10 
or more 2D slices to be acquired each over a breath hold in a sick patient, this could 
easily take 10 or more minutes21,22. During that time, GBCA concentration would be 
dropping after a bolus injection, rendering the T1 maps inconsistent between slices. 
However, contrast agent concentrations vary more slowly and to a lesser degree during a 
constant infusion either following a bolus injection between 10 and 30 minutes, or after 
the first 40 min of a constant infusion only protocol (see figure 2-7). Although we did not 
assess the effect of prolonged acquisition times (with accompanying ongoing changes in 
contrast agent concentrations) on the resulting T1 map,  avoiding the variations in blood 
concentration associated with the use of only  bolus injections of GBCA would minimize 
fluctuations in blood tracer concentrations and give us more accurate and precise 
measurements of ECV. This would also be expected in remote myocardium following 
myocardial infarction, provided myocardial blood flow remains close to 1 ml/min/g as 
has been previously shown in this animal model6,8,23. It will be important to validate this 
concentration dynamic as a function of injection protocol in myocardium with 
compromised blood flow in regions with microvascular obstruction where blood flow is 
severely reduced24.  
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For the clinical assessment of inflammation by [18F]FDG using simultaneous PET/MRI, 
suppression of physiological myocardial glucose uptake is generally achieved by a 
method similar to the one we have used in our study, with the intralipid infusion replaced 
by a high fat diet25. No significant difference was found between measured ECV with 
glucose suppression and non-suppressed myocardium when comparing individual groups. 
When comparing suppressed vs non-suppressed irrespective of injection protocol, there 
was a significant difference (0.21 ± 0.02 vs 0.18 ± 0.01, corresponding to a 13% increase; 
p = 0.002). Further experiments are necessary to investigate whether this effect is from 
the lipid infusion, which could decrease the hematocrit. This may be an important 
consideration for experiments utilizing a lipid infusion while measuring ECV, although 
further experiments are necessary to examine whether the lipid infusion affects the 
hematocrit or another part of ECV.We also saw that ECV appears to increase over the 
initial 18 minutes following the bolus injection protocol. This suggests that to assess ECV 
accurately,  one should wait at least 20 minutes and then perform the T1 map 
acquisitions26,27. Schelbert et al. also reported a small but statistically significant change 
of Ve (extravascular extracellular volume fraction) after bolus injection of GBCA, which 
is consistent with our results27. Clinically, an increase in the measured ECV over 18 
minutes may be relevant if the MOLLI sequence is not acquired at identical post-contrast 
delay times27. This might require careful attention to imaging delay time when using a 
bolus or post-scan correction to compensate for the small increase27.  
While the safety of FDG and GBCA have both been determined independently, to the 
best of our knowledge the compatibility of the two contrast agent mixture has not been 
shown. For instance, the linear and cyclic aminopolycarboxylic acid chelators could 
potentially conjugate to FDG via glycosylation. De-fluorination was another minor 
concern. In this paper, we show an initial assessment at ambient temperature that neither 
attachment of chelate to the FDG nor loss of fluoride were observed. Although this data 
is consistent with the safety of a combined injection, further investigations on the effect 
of physiological temperature during mixing and blood sampling after concurrent injection 
would further increase confidence. 
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In our study we did not see the expected decrease in Ki, a measure of glucose uptake, 
with glucose suppression. When we compare the non-suppressed group to the suppressed 
group independent of injection strategy, suppression did not have a significant effect on 
glucose metabolism (p=0.27, non-suppressed 0.010 ± 0.008, suppressed 0.0063 ± 0.009). 
In all cases the non-suppressed values were below 0.035 ml/min/g. In the suppressed 
group, all were below 0.02, with 11 of the 14 below 0.005 ml/min/g. It is clear that 
suppression worked well for the non-suppressed values above 0.02 but had minimal and 
even contrary results for values already as low as can be achieved with suppression. As 
all animals were fasted but the suppressed group was also given heparin and intralipid, 
perhaps the requirement to fast canines for 12-16 hours prior to anesthetic was sufficient 
to suppress glucose uptake, or the use of only 5 animals may not have provided enough 
statistical power to establish the presence of a statistically meaningful effect (figure 2-6a 
and c do suggest a downward trend). Our results are promising as hybrid PET/MR 
imaging is being used more and it gives the ability to image aspects of inflammation 
through both modalities simultaneously. To this we have shown in a canine model that 
concurrent FDG and GBCA injections can be safely used, and do not affect the glucose 
metabolism and ECV measurements which reduces overall imaging time and ensures 
optimal registration of the PET and MRI images.  
However, our work has limitations: a) While the sample size of this experiment is 
relatively small, this research provides a starting point for future clinical or pre-clinical 
experiments. Power analysis has shown that significant differences in ECV for 
suppressed vs unsuppressed tissue could be reached in each injection protocol with as 
few as 7 animals in CI and bolus followed by CI group whereas a total of 13 animals 
would be needed in the bolus only group if the mean and standard deviation were the 
same as in the current groups. b) Only partition coefficient, and not ECV, was evaluated 
due to lack of hematocrit data, but results can be directly translated to ECV for clinical 
relevance as the only difference between partition coefficient and ECV is hematocrit 
correction and thus a hematocrit of 0.45 was assumed for this study. c) The use of a linear 
gadolinium chelator, Gd-DTPA (Magnevist) in our experiment has been discontinued 
(after the start of this experiment) in favour of macrocyclic GBCA’s due to association 
with an increased risk of brain retention. However, ECV represents a physiological 
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parameter and is derived from the ratio of T1 signal values and is likely not affected by 
type of extracellular GBCA used and therefore our results can still be translated for 
clinical relevance. d) Hybrid PET/MRI is currently not in widespread clinical use. While 
this may change as the modality becomes more accessible and more methods are 
developed, not many research centres and hospitals will currently be able to take 
advantage of these results.  
2.5 Conclusion 
Suppression of myocardial uptake of [18F]FDG, through a continuous lipid infusion and 
an intravenous heparin injection, has no effect on ECV using GBCA compared to 
unsuppressed tissue. Additionally, the infusion protocol used (bolus alone, CI alone, 
bolus followed by CI) had no effect on the calculated ECV at equilibrium, however, ECV 
measured using a bolus of Gd-DTPA was underestimated if measured prior to the first 15 
minutes following injection. Lastly, we have shown that combining Gd-DTPA and FDG 
for concurrent injection for hybrid imaging showed no changes in pH or radiochemical 
purity of [18F]FDG. Therefore, simultaneous PET/MRI is promising as it gives the ability 
to accurately measure complementary aspects of inflammation through both modalities, 
specifically cardiac inflammation alongside diffuse fibrosis and this has potential 
application in remote myocardium. 
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Chapter 3  
3 Tracking the progress of inflammation with PET/MRI in a 
canine model of myocardial infarction 
3.1 Introduction 
After a myocardial infarction (MI), patients remain at risk of adverse events, including 
heart failure1. Risk factors for these adverse events include infarct size2,3 and extent of 
microvascular obstruction4. Both are independent predictors of left ventricular 
remodeling.  Inflammation also plays a key role in the response to infarction and its 
evolution will play a key role in determining how the left ventricle remodels.  Both MRI 
and FDG-PET may provide insights into the evolution of myocardial injury and 
inflammation. 
 Using MRI, T1 maps can be obtained and used to measure the extra-cellular volume, an 
indicator of tissue edema, a common accompaniment of inflammation. ECV is elevated 
within infarcted tissue post-MI, starting in the first few hours5. However, little is known 
about the ECV in remote non-infarcted, non-ischemic myocardium as the left ventricle 
remodels 6.  In such tissue, fibrosis, cellular inflammation and edema may evolve 
gradually which would result in a slow increase in ECV, which might only be measurable  
over extended periods of time (months)7,8.  
In addition to defining the extent of irreversible injury, the delayed enhancement protocol 
also provides a volume measure of microvascular obstruction within the infarct which we 
designate hereafter as Infarcted Obstructed Tissue or IOT. IOT has very compromised 
blood flow with reduced tracer delivery.  Little is known about the ECV in the IOT and 
how it changes in time post-MI.  
In order to quantitate ECV in remote tissue (RT), infarcted tissue excluding any region 
with significant microvascular obstruction, Infarcted Non-Obstructed Tissue or INOT, 
and IOT, single-slice breath hold T1 maps need to be acquired spanning the entire heart9–
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11. However, this requires acquisition during which the concentration of GBCA in the 
blood and tissue should not be changing significantly, as it normally would following a 
bolus injection9–11. However, it has been known for some time that a bolus injection 
followed by a constant infusion of GBCA, given the correct timing and dose distribution 
between the bolus and constant infusion, achieves relatively rapid constant blood 
concentrations9–12. Despite this, few studies have investigated just using a prolonged 
constant infusion to  measure ECV in the RT, INOT and IOT13.  
Post-MI, cellularly mediated inflammatory processes clear out myocardial cellular debris 
and stabilize the region of infarction with scar tissue. When using FDG to image 
macrophage mediated cardiac inflammation, an important consideration is effective 
suppression of the glucose uptake by cardiomyocytes to get an accurate picture of 
inflammation, without the confounding effect of myocardial glucose uptake. This is 
generally achieved with one or more of: fasting, a high-fat diet, heparin injection, and in 
animals, a lipid infusion14. In addition to the concern regarding suppression of myocardial 
glucose uptake, an additional concern with FDG PET imaging in acute MI  is the 
potential effect of IOT on the apparent inflammation profile: lower FDG activity in the 
center of the infarct (i.e. the IOT) may be primarily the result of reduced delivery of this 
tracer as a result of the severely compromised flow. Since myocardial infarction patients 
with IOT have poorer outcomes it is imperative to be able to accurately quantitate the 
inflammatory processes within this region (without the confounding effects of 
compromised tracer delivery), in order to plan future interventions to improve prognosis. 
Previously, a constant infusion has been used in the brain to penetrate the ischemic region 
post-stroke15. We propose that a constant infusion of Gd-DTPA and FDG would allow 
penetration of the IOT to allow better characterization of the inflammatory response, both 
macrophage mediated, and that associated with tissue fibrosis and edema, without the 
constraints of compromised tracer delivery.  
Here we have investigated the potential application of a simple combined constant 
infusion of Gd-DTPA and FDG to quantitate inflammation, ECV and function in RT, 
INOT and IOT in a canine model of permanent coronary artery occlusion from 3 to 42 
days post-MI.  
78 
 
3.2 Methods 
3.2.1 Animals and Surgical Preparation 
This study was approved by the Animal Care Committee of Western University. Eight 
adult, female, bred-for-research hounds were used. Anesthesia for surgery and imaging 
was induced using Propofol and maintained with 1.5% – 2% isoflurane. Animals 
underwent imaging at baseline (n = 5), 3-4 (n = 6), 7-8 (n = 7), 14-15 (n = 6), 21-22 (n = 
8) and 38-44 (n = 8) days post-MI (Figure 3-2). Due to technical difficulties, not all 
animals were imaged at all time points. MI was induced by permanently placing a snare 
ligature around the left anterior descending coronary artery during left thoracotomy.  
3.2.2 PET Imaging 
Animals were fasted between 16 and 21 hours before the start of imaging. To further 
suppress myocardial glucose uptake, twenty minutes before the constant infusion of 
FDG, 2000 units of heparin were administered intravenously and an infusion of 20% lipid 
(Intralipid; Baxter Healthcare Corporation) at a rate of 0.25 mL/min/kg was administered 
intravenously over a 50-minute period starting immediately after the administration of 
heparin (see figure 3-1 for a sample image). Note that whereas in humans diet and 
heparin are sufficient for 95% suppression14, in canines intralipid infusion is also needed 
as we have previously reported16. 
 
Figure 3-1:FDG uptake at day 7 post-MI, 10 minutes after the end of the constant 
infusion. 
This figure shows the uptake of FDG in the myocardium highlighting the infarcted area, 
7 days post-MI, 70 minutes after the start of the infusion. From left to right, there are a 
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T1 map, a T1 map overlaid with FDG PET and PET only. It should be noted that there is 
some uptake within the entire myocardium and not just the infarct (red arrow). A longer 
washout time would likely eliminate a large portion of this. The method of suppression 
has also been previously used and found to be adequate in this animal model with a bolus 
injection99. This image also highlights the incision site (orange arrow) which shows that 
macrophage FDG uptake is not affected by suppression of myocardial glucose uptake. 
A 60-minute constant infusion of both FDG (0.17 MBq/min/kg; Fludeoxyglucose (18F) 
Injection, produced in-house at the Lawson Cyclotron Facility) and Gd-DTPA (0.004 
mmol/min/kg for a total dose of 0.24 mmol/kg, Magnevist; Bayer Inc.) was started 
simultaneously with the beginning of the list mode PET acquisition. In addition to the 60-
minute infusion, the PET acquisition was extended to a further 10-minute washout in 3 
dogs and a 30-minute washout in 5 dogs. The PET data was reconstructed in 3-minute 
frames using a 3D Ordered Subset Expectation Maximization reconstruction (3 iterations, 
21 subsets, 172 x 172 x 127 matrix size, zoom of 2 and 4 mm Gaussian filter). MR-based 
attenuation correction was achieved using a two-point Dixon MRI sequence and 
segmented into water, fat, lung and air with constant attenuation coefficients for each 
tissue17. The PET voxel size was 2.09 x 2.09 x 2.03 mm.   
3.2.3 Cardiac MR imaging 
MR imaging was started 60 minutes prior to the beginning of the constant infusion. 
Sequences included short axis cine stacks of the left ventricle synchronized to the ECG 
signal (true fast imaging with steady-state free precession (TrueFISP), slice thickness 6 
mm, 256 x 216 voxels, voxel size 1.09 x 1.09 mm, ~12s acquisition time, based on heart 
rate) where each slice was acquired during a breath hold; a 3D T1 weighted image (ECG 
triggered Inversion Recovery sequence with navigator echo for respiratory gating, 256 x 
200 x 112 voxels, voxel size 0.625 x 0.625 x 0.9 mm, ~4 minute acquisition time, based 
on heart and respiratory rate); T1 maps (ECG-triggered modified Look-Locker inversion 
recovery sequence, slice thickness 6 mm, 256 x 144 voxels, voxel size 1.09 x 1.09 mm, 
~12s acquisition time, based on heart rate) in a single breath hold to acquire 2-chamber 
and 4-chamber views of the heart (Siemens Work In Progress). In 7 animals, T1 maps 
and 3D T1 weighted images were acquired in 10 minute intervals. In the other animal, 4-
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chamber view T1 maps were acquired every 3 minutes and a 3D T1 weighted image was 
acquired 70 minutes into the PET scan (i.e. 10 minutes after the infusion was stopped). 
See figure 3-2 for details on the timing of both the MRI and PET data acquisitions. 
 
Figure 3-2: Experimental Protocol. 
After the subject was setup in the MR scanner, MRAC, localizers, pre-contrast images 
and cine images were acquired. During this time, heparin was injected and lipids where 
infused. Then, a constant infusion of Gd-DTPA and FDG was started and T1 maps and 
3D T1-weighted images were acquired in conjunction with FDG list-mode data.  
 
3.2.4 Data Analysis 
3.2.4.1 Regions of Interest 
Regions of interest (ROIs) were manually drawn onto the final Gd-enhanced T1 map 
which was then automatically transferred to all other T1 maps. The ROIs outlined were 
the IOT, the INOT, two samples of RT, and the blood pool. Note that the IOT only 
included tissue with microvascular obstruction and the INOT was all other infarcted 
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tissue, excluding the IOT. The 2D ROIs were then also transferred to the corresponding 
slice of PET data. Figure 3-3 shows the selection of the three regions of interest (RT, 
INOT and IOT) and the selection of the blood pool region within the left ventricular 
cavity all taken 10 minutes after the 60-minute constant infusion. Manual adjustment of 
some images in the series was applied to offset changes in heart position. Edges were also 
avoided when drawing ROIs to minimize partial volume averaging from voxels at the 
myocardial-blood pool border.  
 
Figure 3-3: Region of interest selection post-MI on a 2-chamber T1 map. 
Glucose metabolism and extracellular volume (ECV) measurements were calculated at 
four separate regions (two in remote tissue (RT), one in infarcted not obstructed (INOT), 
excluding tissue with microvascular obstruction, and one in infarcted obstructed tissue 
(IOT)).  
3.2.4.2 Glucose Metabolism 
FDG concentration curves of all ROIs were fit to the Patlak model18 as discussed in 
section 2.2.4. 
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3.2.4.3 Extracellular Volume Fraction 
ECV maps calculated at the 60-minute time point in the constant infusion were used to 
compare changes over time. For the estimation of ECV equilibrium was assumed to be 
reached when the difference in ECV between acquisitions was less than 5%, as done by 
White et al23. 76 out of 868 T1 maps could not be analyzed due to excess noise and were 
excluded. ECV was calculated as discussed in section 2.2.3. 
3.2.4.4 Volumes of IOT and INOT 
To determine the volume of the IOT and INOT, gadolinium-enhanced 3D T1 weighted 
images were segmented by a single observer using the 3D Slicer Segment Editor 
(http://www.slicer.org/)24. Thresholds were determined for IOT, INOT and RT and drawn 
using the Threshold Paint function. The threshold was set for each experiment to exclude 
the IOT and occasionally had to be adjusted between slices. 
3.2.4.5 MRI Measurement of Heart Function 
Using Slicer to analyze the ECG triggered short axis TrueFISP image series, the blood 
pool can be segmented. A single operator defined the blood pool throughout the series 
and determined the phases of the cardiac cycle with the highest and the lowest blood 
volume. These were defined as the end diastolic volume (EDV) and end systolic volume 
(ESV). The ejection fraction (EF) was calculated using the equation,  
𝐸𝐹 =
𝐸𝐷𝑉 − 𝐸𝑆𝑉
𝐸𝐷𝑉
∙ 100%. 
These results were compared to the automatic segmentation generated with commercial 
cardiovascular image analysis software, circle cvi42 (Circle Cardiovascular Imaging Inc, 
Calgary), and were found to be within 5% when the same number of short axis slices 
were used. As circle cvi42 failed in a number of sets of data we report values from Slicer. 
Slices were excluded due to poor image quality, if the aorta was visible or if they were 
past the apex. 
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3.2.4.6 Statistics 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA). All data is presented as mean  standard error of the mean. Repeated-measures 
analysis of variance (ANOVA) was performed on the days post-MI, prior to washout and 
following washout. Comparison of differences in RT, INOT and IOT, as well as during 
washout of Gd-DTPA, was assessed with paired and unpaired two-tailed t tests. A p-
value of <0.05 was considered to be statistically significant. Corrections for multiple 
comparisons were performed using a Bonferroni multiple comparison test.  
3.3 RESULTS 
3.3.1 Volume of IOT and INOT 
 Figure 3-4 shows the T1 maps determined every 10 minutes for one dog. 
Penetration over time into the IOT can be seen. ROIs were drawn on the 73-minute map 
to allow for some washout from the blood pool. Measuring the volume of the INOT 
showed a decrease over time in all animals with a mean starting value of 15174 mm3 at 
day 3 and a final value of 4939 mm3 at day 43, as shown in figure 3-5. Statistical 
differences were observed starting at day 14 (p = 0.014) and then also on day 21 (p = 
0.0031) and day 43 (p = 0.0003).  
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Figure 3-4: 2-Chamber T1 maps throughout the constant infusion at day 7. 
This image shows the influx of tracer into the IOT (blue arrows) and INOT (yellow 
arrows). 
 
Figure 3-5: Change in INOT Volume over Time. 
The INOT volume starts at its highest at day 3 and decreases over 42 days in all 8 
animals. Day 3: n = 7, Day 7: n = 7, Day 14: n =5, Day 21: n = 8, Day 42: n = 6. 
85 
 
3.3.2 Extracellular Volume 
There was a significant increase in RT at minute 60 on day 14 (p=0.0336) and day 21 
(p=0.0205) post-MI compared to the baseline healthy myocardial ECV as shown in figure 
3-6. There was no significant difference in RT ECV on day 3 (p=0.50), day 7 (p=0.086) 
and at day 40 post-MI (p=0.0597) relative to the baseline myocardial ECV. 
 
 
Figure 3-6: ECV in remote tissue post-MI. 
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a) ECV (mean ± SEM) varies in the days following MI in the RT over the duration of the 
scan using the constant infusion protocol. b) ECV values for each canine at each 
respective day post-MI in RT 60 minutes into the scan, at equilibrium, prior to washout of 
Gd-DTPA. * represents a significant difference of (p<0.05)  
 
Figure 3-7: ECV measurements pre- and post-MI in all tissue types. 
ECV measurements were calculated in eight canine subjects measured every 10 minutes 
for up to 90 minutes after starting the constant infusion of Gd-DTPA.  ECV was 
calculated in RT, INOT and IOT at days 3, 7, 14, 21 and 40 post-MI and prior to MI. 
Data represented are mean ± SEM. Constant infusion of Gd-DTPA was terminated at 60 
minutes followed by 30 minutes of washout. Only one canine showed an IOT at day 21 
and no IOT was seen for any canines 40 days post-MI. Figure 3-7 shows how the 
measured ECV varies with time for RT, IOT and INOT. Clearly RT reaches equilibrium 
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as quickly as seen in the normal myocardium measured at baseline with no change 
during washout. The measurement in the INOT reaches equilibrium well within the 60 
min constant infusion at all days except at day 3. The measurement in the IOT does not 
reach equilibrium except perhaps at day 7, though there was still a significant difference 
between the 50 minute and 60 minute timepoints. It is clear that the measurement of ECV 
is not accurate during washout for either INOT or IOT, independent of time, post-MI. 
As shown in Figure 3-7, ECV was significantly elevated in the INOT myocardium at 
minute 60 compared to RT myocardium at all time points post-MI (days 3, 7, 14, 21 and 
40) (p<0.001). 
In the INOT at day 3, there was a significant increase at minute 60 compared to minute 
50 (p=0.024). At all other days post-MI there was no significant difference between 
minute 60 and minute 50 (day 7: p=0.062; day 14: p=0.39; day 21: p=0.47; day 40: 
p=0.11). 
In the IOT, there was no significant difference in ECV at day 3 at minute 50 and minute 
60 (p = 0.17). There was a significant difference between minute 50 and 60 at day 7 
(p<0.01), however, at all other time points there was an insufficient number of canines 
with an IOT to do proper analysis (N=3 for day 14, N=1 for day 21, N=0 for 40 days).  
 
Figure 3-8: ECV measurements in the INOT post-MI. 
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This figure shows ECV values for the INOT tissues for all canines post infarction as a 
function of 60 minute constant infusion followed by 30 minutes of washout. Measured 
ECV is increased during the washout period of Gd-DTPA. 
Figure 3-8 shows ECV values for the INOT tissues for all canines post-MI as a function 
of 60-minute constant infusion followed by 30 minutes of washout. The measured ECV is 
significantly increased during the washout period of Gd-DTPA (see figure 3-9). This was 
also seen for the IOT tissue at day 3 at 70, 80 and 90 min of washout and at day 7 at 90 
min while at days 14, 21 and 40 there was insufficient data for analysis as the IOT tended 
to resolve into INOT. 
 
Figure 3-9: ECV in the INOT 3 days post-MI. 
Measured ECV in the INOT three days following myocardial infarction at minute 60, 
compared to times following washout (10, 20, 30 minutes into washout, p = 0.0035, p = 
0.0181, p = 0.0468, respectively). * represents a significant difference of p<0.05. 
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3.3.3 Patlak Parameter Estimates 
 Figure 3-10 shows the Ki for all 8 animals in remote myocardium as a function of 
time post MI. Although it appears that there was an increase in some animals early post-
MI, no significant changes were seen (day3: p=0.38; day 7 p = 0.32; day 14: p = 0.11; 
day p = 21: 0.19; day 43: p = 0.63).  
 
Figure 3-10: Remote tissue Ki pre- and post-MI. 
Remote Ki shows no significant difference over time though it appears as though there 
may be a rise over the first week. This plot shows the mean and interquartile ranges (box) 
and the maximum and minimum values (whiskers). 
Figure 3-11 shows the glucose metabolism for the INOT, Ki, as a marker of glucose 
metabolism, significantly exceeds baseline (0.00514+/- 0.00045) at all points other than 
day 43, when glucose metabolism returns to the baseline value. While day 3 is not 
significantly different from day 7, it is higher than all other values, showing that the 
inflammatory response appears largest within the first week of infarct. This decrease over 
time appears to be linear with an r value of 0.918 (p = 0.0278). 
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Figure 3-11: Ki in INOT post-MI. 
INOT Ki decreases linearly (dashed lines indicate confidence interval) over time, 
returning to pre-infarct values (0.00514+/- 0.00045) at day 43. Ki in the INOT is 
significantly different from day 3 at day 14 (p=0.0143), day 21 (p=0.0031) and day 42 
(p=0.0003). 
The distribution volume in the INOT, calculated with the Patlak model, also undergoes 
significant changes post-MI, where days 7 (p = 0.0199), 14 (p = 0.0015), 21 (p = 0.0001) 
and 42 (p < 0.0001) are significantly higher than day 3 as shown in figure 3-12.  
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Figure 3-12: Distribution volume (y-intercept) calculated using the Patlak model in 
the INOT.  
Days 7 (p=0.0199), 14 (p = 0.0015), 21 (p = 0.0001) and 42 (p < 0.0001) are 
significantly higher than baseline though a lot of variation was seen on day 7.  
Glucose metabolism in the IOT is increased at days 3 (p = 0.0332) and 7 (p = 0.0042) 
relative to baseline. There were not enough values for subsequent days to test 
significance, although in the remaining animals, it does appear to stay elevated. 
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Figure 3-13: End-systolic volume, end-diastolic volume and ejection fraction over 
time post-MI. 
As in human patients, there is an initial drop in ejection fraction (p=0.0013) which then 
recovers in the following week and remains near baseline. This initial decline can be 
explained by an increased ESV (p = 0.0127) with steady EDV.  
3.3.4 Measurements of Cardiac Function 
 Figure 3-13 shows the ejection fraction (EF), end-diastolic volume (EDV) and 
end-systolic volume (ESV) for all animals. A sharp decrease in ejection fraction is visible 
at day 3 (p = 0.0013) before it returns to a baseline value at day 7. The end diastolic 
volume on the other hand does not show a difference while the ESV increases on day 3 (p 
= 0.0127).   
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3.4 Discussion 
In this study, we have applied PET/MR using a combined infusion of a gadolinium-based 
contrast agent and FDG to assess cell-based inflammation, myocardial fibrosis, and 
edema, in multiple regions of potential myocardial injury following an acute myocardial 
infarction.  Accurate assessment of these processes can be compromised by issues of 
reduced tracer delivery, particularly within the central core of an infarction, where 
microvascular obstruction can markedly reduce blood flow.   A single bolus injection of 
either tracer may not allow adequate penetration of these tracers into these areas of 
markedly compromised flow. 
Although our group has previously demonstrated that concurrent constant infusions of 
Gd-DTPA and FDG can provide valid measures of ECV and 18F-FDG in normal 
myocardium13, this is the first time this injection strategy has been used to investigate RT, 
INOT and IOT post-MI, and sequentially over several weeks. It is evident from figure 3-
6a) that identical ECV values in RT can be measured after 20 to 30 minutes after the 
onset of a constant infusion until 30 minutes after terminating the constant infusion 
implying that the GBCA must be being cleared similarly from the RT and blood.  
The ECV in the INOT reached equilibrium between 50 and 60 minutes of onset for days 
7 – 40 and likely did at the 60 minute time point for day 3 (see figure 3-7), demonstrating 
that even with reduced blood flow in the INOT tissue, a 60-minute wash in was sufficient 
to obtain accurate values of ECV. However, the 60 min constant infusion in the IOT 
appears to not have reached equilibrium within the tissue and hence it is unlikely that the 
estimate of ECV is accurate. The data presented in figure 3-5 and figure 3-7 at 7, 14 and 
21 days suggests that ECV of IOT may actually be similar to that of INOT at the end of 
the 60 min infusion. However, in the early days following infarction, at day 3, the IOT 
measured ECV was comparable to RT and much lower than the measured value in INOT. 
Nevertheless, compared to a bolus injection, significant penetration does occur with the 
60 min constant infusion11,16,25. 
Unlike RT, measurements of ECV during washout in the INOT and IOT should not be 
used as they were significantly elevated at all washout time points as shown in figure 3-7, 
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3-8 and 3-9. This is presumably because the blood flow is lower in the IOT and INOT 
and thus dramatically reduces Gd-DTPA clearance in the myocardium compared to 
blood, meaning that measured ECV appears artificially elevated26. This is the opposite to 
the beginning of the scan, where the ECV is underestimated as the tracer entering the 
INOT lags behind Gd-DTPA concentrations in the blood. Note that these observations 
regarding achieving equilibrium in RT, INOT and IOT for GD-DTPA imply that FDG, 
which was concurrently injected with Gd-DTPA, would behave similarly. 
We found a significant increase in ECV in the RT at days 14 and 21 post-MI, but not at 
days 3 and 7. Increases in ECV in RT may reflect more generalized but less intense tissue 
edema and/or an early fibrotic response, not just limited to the area of acute ischemic 
injury, a pattern that has been  shown in rats8,28. Cleutjens et al. have shown increased 
collagen protein deposition in rats in both infarcted and non-infarcted areas through 
upregulation of type 1 and type 3 collagen mRNA transcription8. This could potentially 
lead to the ECV increases that we observed  post-MI8,28.  At day 40, there was a p value 
of 0.06 for ECV in remote myocardium. A larger sample size could potentially have 
shown elevated ECV, 40 days post-MI. ECV calculation provides important, non-
invasive insight into the pathophysiological mechanisms of cardiac remodeling post-MI 
and may serve as an important source of diagnostic, therapeutic and prognostic decision 
making10,29–31. Specifically, the change in ECV in remote non-infarcted tissue provides 
strong evidence that there is a pathological process evolving in the early weeks post-
infarct8,28,32. Future work is needed, such as validating this through measuring amount of 
fibrosis in histological tissue samples taken from RT and comparing it to tissue from 
sham treated animals. 
Figure 3-13 shows that the functional assessments have a similar timeline for evolution of 
heart function as human patients post-MI with reduced ejection fraction27. There is a 
sharp decrease in ejection fraction at day 3 and recovery over the subsequent time points.  
 
The decrease in the INOT volume using the 3D T1 weighted images (Figure 3-5) has 
underscored a long-standing debate. This decrease likely does not represent a degree of 
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tissue repair but rather reflects permanently damaged myocardial tissue, in essence, 
shriveling over the days and weeks post infarct. Note this data was taken while the blood 
and tissue concentrations were kept constant in the RT and to a large extent in the INOT 
tissue due to the constant infusion.  
The FDG results that we observed were not as consistent as the ECV results. This is 
partially attributable to the lower spatial resolution of cardiac -FDG PET in comparison 
to GBCA MRI, leading to potential partial volume issues in the discrimination of IOT 
from INOT. However, there should be a minimal partial volume effect from the left 
ventricular blood pool when assessing RT as myocardial edges were not included. As 
shown in 3-9 there is a trend of an increase in Ki from baseline at days 3, 7, 14, and 21 
though no significant changes were observed day3: p=0.38; day 7 p = 0.32; day 14: p = 
0.11; day 21: p = 0.19; day 43: p = 0.63. These values are also similar to what was found 
by Herrero et al in normal canine myocardium during suppression33. Figure 3-6b) shows 
increases in ECV at days 7, 14 and potentially 43 days. Although not large effects, this 
suggests that increases in ECV (potentially edema and fibrosis) is accompanied by cell 
based inflammation in RT. Note how both results (Figures 3-6b and 3-10) suggest that by 
43 days both are proportionately reduced. If fibrosis had developed it would seem 
unlikely that it would have resolved, suggesting that perhaps edema associated with the 
18F-FDG detected inflammation may have started to resolve.  
Glucose metabolism in INOT decreased with time as shown in figure 3-10, with Ki 
highest at 3 days (0.0125 ml/min/g) decreasing to approximately normal tissue values by 
day 43. In contrast, the Patlak analysis for INOT (see figure 3-8) showed a significant 
increase in the extravascular exchangeable volume. This decrease in glucose metabolism 
in the INOT suggests that the number of metabolically active macrophages is decreasing 
or are being converted into M2-like macrophages, which take up less FDG than M1-like 
macrophages26. It appears that the INOT experiences the highest level of inflammation 
within the first week following which it declines and returns to baseline by day 43. The 
IOT glucose metabolism was also significantly increased for the first week but could not 
be evaluated as a separate region distinct from the surrounding INOT after that due to the 
decreasing number of animals with an IOT at the later time points as there is apparent 
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recovery from the initial microvascular injury. This strengthens the notion that anti-
inflammatory treatment would be most effective within the first two weeks, but it also 
shows that the IOT may be an important factor influencing the perseverance of 
inflammation, especially since glucose metabolism in that region is probably 
underestimated. As we have shown here, even after the 60 min constant infusion, Gd-
DTPA concentration was still increasing. This would suggest a corresponding increase in 
FDG concentrations within the IOT and that the methodology used in the experiments 
reported here underestimated the true glucose metabolic rate in the IOT.  
Limitations of this study include the small number of animals, but even more so, the 
small number of animals with an IOT that was sustained through the period of 
observation, although this pattern of resolution of the regions of microvascular 
obstruction is by itself noteworthy. Another limitation is that not all animals could be 
imaged at every timepoint. While most animals had an IOT at day 3 and day 7, they 
disappeared at day 14, for all but two animals. More animals would also let us study the 
RT in more detail, since there is an increase in ECV on days 14 and 21 which may 
correspond to an inflammatory response. We have also found that ECV may be affected 
by myocardial glucose uptake suppression, i.e. is larger by 13% in healthy myocardium13. 
Since all of these animals were suppressed equally, the trends found should not be 
affected, but actual ECV values may be slightly lower. 
3.5 Conclusion 
Here we have shown rigorous longitudinal measurements of inflammation and ECV, 
measured during a combined infusion of FDG and GBCA. ECV in remote myocardium at 
14- and 21- days post-MI was significantly greater than at baseline. The change in ECV 
in remote non-infarcted tissue provides strong evidence that there is a pathological 
process evolving in the early weeks post-infarct. As the concentration of FDG in the IOT 
continues to rise by the end of the constant infusion, it stands to reason that a bolus 
injection of FDG would underestimate the glucose metabolism in the IOT.  
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Chapter 4  
4 Myocardial glucose suppression interferes with the 
detection of inflammatory cells with FDG-PET in a 
canine model of myocardial infarction 
4.1 Introduction 
Following a myocardial infarction (MI), heart failure may develop due to a number of 
factors such as extent of initial myocardial injury, but is also influenced to a major extent 
by dysregulation of inflammation in response to the original insult1. MRI measurements 
have shown promise in detecting characteristics associated with an increased risk of heart 
failure, including infarct size2,3, presence of hemorrhage and presence and size of 
microvascular injury/obstruction4,5, hereafter referred to as Infarcted Obstructed Tissue 
(IOT). Extracellular volume (ECV) measurements, generally associated with tissue injury 
and/or edema,  in particular, provides a sensitive measurement of myocardial fibrosis6. 
To acquire ECV measurements with MRI, T1 maps pre- and post-contrast are required7,8. 
Our group has previously shown how a constant infusion of a gadolinium-based contrast 
agent (GBCA) can be used to measure ECV post-MI using a 60 min constant infusion9,10. 
FDG-PET imaging allows assessment of cell-mediated inflammation but may not be able 
to distinguish between uptake of the tracer by pro-inflammatory (neutrophils and M1 
macrophages) vs. anti-inflammatory (M2 macrophages) cells. Further, post-MI, to make 
FDG-PET specific for inflammation, uptake of FDG by non-infarcted myocardium has to 
be suppressed as completely as possible so that the residual uptake of glucose is specific 
and limited to that by the resident and invading inflammatory cells.   In humans, 
sequestration of the FDG tracer by myocardium can be achieved with fasting and the 
injection of heparin11, which enhances free fatty acid utilization and decreases glucose 
uptake by myocardium. In the canine model, myocyte glucose uptake suppression can be 
achieved through a combination of fasting, the injection of heparin and a lipid infusion at 
the time of FDG administration. However, it is not known if these suppressive techniques 
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may also affect the degree of uptake (i.e. the metabolic activity) by the inflammatory 
cells (macrophages). Here, we have investigated this question in the canine model of MI.  
Another issue to be considered that may affect the accurate determination of the degree of 
inflammation within the infarct core is the potential partial volume effect of IOT on the 
Infarcted Non-Obstructed Tissue (INOT). Due to the very compromised blood flow, PET 
tracers injected as a bolus do not penetrate the IOT. As the size of the IOT is often too 
small to be resolved from the INOT with PET, the presence of IOT may cause INOT 
FDG uptake to appear artificially lower. 
Here we report on our investigation of these potential limitations. We have evaluated the 
use of a prolonged 150 min constant infusion of FDG and Gd-DTPA instead of a bolus 
injection. This prolonged constant infusion allows the investigation of the effect of 
suppression on uptake of FDG by inflammatory cells through the tracking of the 
metabolic activity before, during and after the use of myocardial suppression techniques.  
Further, this will also provide some insight into the pattern and degree of inflammatory 
activity within the central IOT. 
4.2 Materials and Methods: 
4.2.1 Animal Preparation 
The care and treatment of the animals was in accordance with the University of Western 
Ontario Council on Animal Care (Animal Use Subcommittee) guidelines. The adult, 
female, bred-for-research hounds weighed 18-23 kg. Anesthesia for all procedures was 
induced using propofol and maintained with 1.5% - 2% isoflurane (Forane, Baxter). In 
experiment one, six animals were studied at baseline (BL) twice, to determine the effect 
on glucose uptake in normal myocardium of heparin alone (BL1) and of heparin 
combined with lipid infusion (BL2). Combined with fasting, preliminary data indicates 
that the combination of heparin and lipid is the most effective approach to suppression in 
canines12.  In experiment two, five of the animals from experiment one and two 
additional animals, which did not undergo the procedures in experiment one, underwent a 
procedure to induce a myocardial infarction. The left anterior descending coronary artery 
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was permanently ligated during left thoracotomy. Five days after the surgery, the seven 
animals were imaged. As only one imaging procedure was possible at five days, the 
effect of suppression of glucose metabolism in the remote tissue and in the infarcted 
tissue was investigated using both a heparin injection and the lipid infusion. Heparin was 
administered as an intravenous bolus of 2000 units and a 20% lipid infusion (Intralipid; 
Baxter Healthcare Corporation) was given intravenously over a 50 minute period at a rate 
of 0.25 ml/min/kg. Since all canines were of a similar weight (20-23kg) the same dose of 
heparin was used. Before each scan, the blood glucose level was measured with a 
glucometer. After the post-MI imaging at 5 days, animals were given 20mL propofol and 
then euthanized with an injection of KCl (30mL administered intravenously).  
 
Figure 4-1: 150-minute constant infusion protocol.  
Cine images, 3D T1 weighted images and T1 maps were acquired pre-contrast. PET list-
mode acquisition was started simultaneously with the constant infusion of Gd-DTPA and 
FDG. Heparin injection and lipid infusion were done 40 minutes into the constant 
infusion.  
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4.2.2 Injection Protocol 
In previous work, we have established that a simultaneous constant infusion of both Gd-
DTPA and 18FDG is an effective approach to measure the extracellular volume (ECV) by 
MRI and the glucose metabolism (MRGlu) by PET9. Unlike the typical approach using a 
bolus injection, a prolonged constant infusion can be easily modelled to monitor the 
effects on ECV and MRGlu of different interventions such as glucose suppression. In this 
study, a 150 min constant infusion was implemented. Note that as the animals required 
fasting to allow anesthesia, there is already a level of glucose suppression that varies 
between animals. In the first baseline scan (BL1), a bolus of heparin was administered 40 
minutes after the start of constant infusion  while in BL2 and post-MI, in addition to the 
heparin injection, a constant infusion of intralipid was begun and continued for 50 
minutes. In all cases, the ECV and MRGlu were determined for three time intervals 
during the constant infusion: from 10 to 40 min, 60 to 90 min and from 120 to 150 min. 
These three time intervals have been hereafter identified as “before”, “during” and “after” 
glucose suppression. During the entire 150 min constant infusion, Gd-DTPA was 
administered intravenously at 4 µmol/min/kg and FDG at 0.17 MBq/min/kg. 
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Figure 4-2: FDG uptake and T1 maps 5 days post-MI pre- and post-suppression. 
Images were taken at 40 minutes (before suppression), 90 minutes (during suppression) 
and at 150 minutes (after suppression).  
4.2.3 PET/MRI Protocol 
All scans were done on a 3T PET/MRI (Siemens Biograph mMR). The animals were 
placed in the right lateral recumbent position and 3 electrodes were positioned on the 
chest to obtain an ECG reading. The protocol is shown in figure 4-1 with the 150 min 
constant infusion started at 40 min after the start of the imaging to allow for set-up and 
baseline MRI acquisitions needed for the ECV calculation. 
Cardiac T1 maps (4-chamber view of the heart) were acquired with a modified Look-
Locker inversion recovery (MOLLI) sequence13 (ECG-gated, 35° flip angle, 256 x 218 
matrix size, 300 mm x 255.5 mm field-of-view, 6 mm slice thickness, 400ms repetition 
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time, 1.12ms echo time) during breath hold at pre-contrast and then every 10 min after 
the concurrent infusions. PET data was acquired in list-mode throughout the 150 min 
constant infusion and subsequently reconstructed in 3-minute frames using a 3D Ordered 
Subset Expectation Maximization (OSEM) reconstruction (3 iterations, 21 subsets, 172 x 
172 x 127 matrix size, zoom of 2 and 4 mm Gaussian filter). Attenuation correction was 
achieved using a two-point Dixon MRI sequence and segmented into water, fat, lung and 
air with constant attenuation coefficients for each tissue. The PET voxel size was (2.09 x 
2.09 x 2.03) mm3. 
4.2.4 Image Analysis 
Figure 4-2 shows a typical hybrid PET/MRI image set acquired at 60 and 150 min into 
the 150 min constant infusion. Note that, due to the intrinsic hardware registration of the 
PET and MRI subsystems, regions of infarct identified on an MRI image are 
automatically registered to the PET images. However, as PET images are not corrected 
for respiratory motion whereas MRI images are the registration is compromised. Image 
analysis was performed using 3D Slicer (Open Source, BSD License) and MATLAB 
(Mathworks, R2019a). As shown in figure 4-3, manually drawn regions of interest 
(ROIs) in the 4-chamber view were used to identify the healthy myocardium and the left 
ventricular blood pool for the baseline experiments. Post-MI, three regions were 
identified and manually outlined by an experienced observer: remote tissue (RT), 
infarcted non-obstructed tissue (INOT) and infarcted obstructed tissue (IOT). Once the 
ROIs were defined, they were used as a template and copied to the rest of the images in 
the series. Manual adjustment of some images in the series was applied to offset changes 
in heart position. Edges were also avoided when drawing ROIs to minimize partial 
volume averaging from voxels at the myocardial-blood pool border.  Dynamic T1 values 
(pre- and post- Gd-DTPA administration) and FDG activity concentration were measured 
in each ROI. 
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Figure 4-3: Regions of interest at 5 days post-MI used for the 150-minute constant 
infusion protocol. 
Regions of interest as defined on a T1 map 60 minutes after the start of the infusion. Red 
represents the IOT, yellow the INOT and blue the RT. 
4.2.5 Volumes of IOT and INOT 
Volumes were manually drawn on 3D T1 weighted images by an experienced observer at 
30 and 150 minutes into the constant infusion.  
4.2.6 Extracellular Volume Determination 
ECV was calculated as discussed in 2.2.3. 
 
4.2.7 Glucose Metabolism  
𝐾𝑖 was extracted for all ROIs in all studies as discussed in 2.2.4 and the metabolic rate of 
glucose (MRGlu) was calculated by multiplying 𝐾𝑖 by the blood glucose level, taken 
before the study. 
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4.2.8 Histology 
 After the experiment 2 imaging session, the hearts from 5 of the subjects were extracted 
and imaged with PET/MRI. Three regions were visually identified on the left ventricle: 
the centre of infarct, edge of infarct and remote tissue. Samples were fixed, frozen and 
embedded in optimal cutting temperature compound (OCT), and subsequently sectioned 
at 5-6 μm thickness, as previously described19,20. Immunohistochemistry using primary 
and fluorophore-conjugated secondary antibodies was conducted as previously 
described19,20. In brief, tissue sections were incubated with blocking buffer in 10% serum 
for 30 minutes at room temperature followed by incubation with primary polyclonal or 
monoclonal antibodies for 1h at room temperature in a humidified chamber. These 
antibodies were used to identify macrophages (CD68 (ab955) 1:200 dilution) and glucose 
transporter 1 (Glut1 (orb157188) 1:1000 dilution). Samples were rinsed twice in 
phosphate buffered solution (PBS) and incubated for 2h at room temperature with 
secondary antibodies (Donkey anti rabbit 488 (A21206 ) 1:1000 dilution; Donkey anti-
mouse 594 (A21203) 1:1000 dilution). Sections were washed twice with PBS, incubated 
8 min with DAPI nuclear stain (1:1000), and mounted with ProLong Diamond antifade 
(Life Technologies) to prevent the tissues from photobleaching. 
           High resolution images were captured with a Nikon A1R Confocal Microscope at 
60x magnification using an oil immersion lens. Five random fields of view were acquired 
for each of 4 tissue sections per sample with the exposure time, gain and look up tables 
set the same for all tissue sections. Therefore, each sample (reported as data points in all 
graphs) reflects an average of 4 technical replicates. 
          Images of CD68 and GLUT1 were analyzed with FIJI 1.49v, a distribution of 
ImageJ software (National Institutes of Health, Bethesda). Punctate staining patterns were 
quantified using the RenyiEntropy algorithm, an entropy-based approach that 
distinguishes the positive punctate signals within the cells from the background. The 
integrated density represents the mean intensity of the positive signal above a certain 
threshold in scaled units divided by the area in pixels. The integrated density threshold 
was set such that the entropies of distributions above and below the set threshold are 
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maximized. Therefore, this algorithm only captured the high intensity punctate staining 
patterns and did not calculate any background staining of these images. 
4.2.9 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA). All data is presented as mean  standard error of the mean (SEM). Paired two-tailed 
t-tests were performed to compare values before, during and after suppression. A p-value 
of <0.05 was considered to be statistically significant. Bonferroni’s method was done to 
correct for multiple comparisons when comparing multiple treatment’s means. 
4.3 Results 
4.3.1 Effect of Suppression on metabolic rate of glucose 
consumption 
As shown in figure 4-2, glucose suppression using heparin and an infusion of intralipid 
has the desired effect of suppressing remote myocardial tissue and thereby highlighting 
the inflammatory activity within the infarcted zone. As heparin was injected at 40 
minutes and the lipid infusion was started at the same time, suppression was seen on the 
FDG time-activity graphs at 60 minutes. At 150 minutes, there is a higher concentration 
of FDG in the infarcted zone compared to the 60 minute time point. This is also 
highlighted by the graph in figure 4-4, showing the FDG uptake quantitatively over time 
in one animal.  
When we analyse the metabolic rate of glucose in all tissues using Patlak graphical 
analysis, a significant difference is seen from before glucose suppression to during, with 
a reduction in the metabolic rate, and after, as shown in figure 4-5. Using both heparin 
injection and lipid infusion (BL2), a significant difference is seen in healthy tissue from 
before to during and after suppression. However, using heparin only (BL1) this effect is 
not as large, with significance only reached between before and during but not before and 
after suppression. This may mean that heparin alone is not as effective in suppressing 
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glucose metabolism as the combination of heparin and lipid infusion. Post-MI, MRGlu in 
both INOT and RT are significantly reduced as shown in figure 4-5. Before suppression 
there is no significant difference in MRGlu between INOT and RT but during and after 
suppression, MRGlu is significantly higher in the INOT.  
 
Figure 4-4: FDG activity concentration over the course of a 150-minute constant 
infusion in one representative animal. 
During the first 60 minutes, INOT and remote tissue rise at almost the same rate but 
when suppression takes effect, the slope of the remote tissue is strongly reduced while in 
INOT it is only reduced slightly. Vertical bars show the time during which lipid infusion 
is applied.  
4.3.2 Effect of suppression on extracellular volume 
As shown in figure 4-6 with either heparin alone (BL1) or heparin with lipid infusion 
(BL2), there is no significant difference in ECV measurements in healthy tissue between 
before, during and after, highlighting that neither heparin nor intralipid infusion affect 
ECV measurements. Post-MI, there is also no significant effect of suppression in the RT 
and INOT on ECV.  
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Figure 4-5: Metabolic rate of glucose consumption at baseline and 5 days post-MI. 
Metabolic rate of glucose consumption decreases in all cases when suppression is 
applied. However, when using heparin only (BL1), there is no significant difference from 
before suppression to after. It should also be noted that post-MI, MRGlu does not 
decrease as much as in the remote tissue even though their starting points are similar. No 
significant differences were found between during suppression and after suppression.  
 
Figure 4-6: Suppression of myocardial glucose uptake does not affect ECV at 5 days. 
There is no significant difference between suppression by heparin only and heparin and 
lipid infusion. Suppression of myocardial glucose uptake did not significantly affect ECV. 
It should be noted that the ECV in the INOT was approximately twice as large as in 
remote tissue. 
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4.3.3 Penetration of infarcted obstructed tissue 
As shown in figures 4-2 and 4-7, there is a degree of penetration of Gd-DTPA, and 
therefore likely FDG, into the IOT. It appears that the FDG activity in the IOT is rising 
linearly over the course of the infusion. The apparent size of the IOT is also greatly 
reduced in the three animals with an IOT (69%, 93% and 93% reduction in IOT volume 
from 30-150 min) when the measurement after 30 min of CI is compared to the end of the 
constant infusion i.e. at 150 min due to progressive penetration of the tracer into the areas 
of most compromised flow during the course of the infusion.  
 
Figure 4-7: IOT and INOT volume 5 days post-MI. 
While only three animals had an IOT, in these animals, the IOT volume decreased by 
69%, 93% and 93%, showing some penetration over time of the IOT. INOT volume on the 
other hand remained the same.  
4.3.4 Histology 
As shown in figure 4-8, there was a significant increase in CD68 expression in the centre 
of the infarct compared to the edge of the infarct and in the remote tissue which were not 
significantly different. There was no difference seen in GLUT1 expression for all regions.  
114 
 
 
 
Figure 4-8: GLUT1 and CD68 expression 5 days post-MI. 
No significant differences were seen in the GLUT1 expression in the center of infarct, 
edge of infarct and remote tissue. However, CD68 expression was higher in the center of 
infarct than at the edge of infarct and in the remote tissue. Representative histological 
images of each are shown on the left.  
4.4 Discussion 
Myocardial glucose suppression has previously been assumed to only affect 
cardiomyocytes but not inflammatory cells such as macrophages21. This has been largely 
an unquestioned assumption in publications dealing with protocols associated with the 
needed suppression of FDG uptake in normal myocytes in order to visualize 
inflammation in diseases like cardiac sarcoidosis. Here we show that there is a significant 
effect of suppression “within” infarcted tissue (figure 4-5), suggesting either an effect of 
suppression on macrophages or alternatively, the presence of a significant volume of 
viable myocytes in the infarcted region, that are subject to the same metabolic effects of 
suppression on the cardiomyocytes within the non-infarcted regions. Considering the 
large increase in extracellular volume (approximately double) within the infarcted region, 
it is unlikely that there is a large presence of viable myocytes. This potential effect of 
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suppression on inflammatory cells may make FDG-based PET imaging less sensitive to 
inflammatory activity, highlighting the need for tracers that are not only specific for the 
presence of inflammation but whose uptake is not confounded by the metabolic state 
present at the time of injection and during the period of imaging.  
The difference in MRGlu results at baseline supports our previous work9 showing that, in 
the canine model, to achieve adequate suppression of myocardial glucose uptake, 
combining a heparin injection with lipid infusion performs better than a heparin injection 
alone. However, the variability of FDG uptake in normal myocardium due to fasting 
alone, prior to anaesthesia, makes it difficult to compare values before glucose uptake 
suppression to after suppression.  
ECV measurements, on the other hand, do not appear to be affected by heparin or lipid 
infusion with no significant difference seen within each baseline scan but also not 
between BL1 and BL2. In a previous study, we found a trend towards higher ECV with 
the use of heparin and lipid infusion when compared to fasting alone when the ECV was 
measured at 14 and 21 days post MI 9. This implies that this increase seen was not related 
to an artifact associated with changes in haematocrit due to the constant infusion 
protocol.  
While only three animals had a visible IOT, in these animals the apparent IOT volume 
decreased by 69%, 93% and 93% after a 150 minute constant infusion of Gd-DTPA. Not 
only does this show that Gd-DTPA is slowly penetrating into the IOT (the concentration 
will slowly continue to increase until the extravascular volume is “filled”) but it also 
suggests that measurement of inflammation in this region using PET imaging is possible 
if corrections are developed for the impact of this slow delivery of FDG. Due to the 
resolution of PET, the IOT also presents a major partial volume problem for the INOT 
and penetrating it with the tracer would make quantification of inflammation within the 
INOT less affected by partial volume artefacts and therefore more accurate.   
Histology shows that GLUT1 expression is the same in infarcted tissue as in remote 
tissue; this similarity lines up well with the MRGlu before suppression in RT and INOT 
which is also not significantly different. While histology shows GLUT1 expression to be 
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the same in the infarct as in the remote tissue, the CD68 expression is more than twice as 
high in the infarct as in the remote tissue. Since ECV has gone up, there must be more 
GLUT1 receptors expressed per cell in macrophages at 5 days post MI. Previously, 
GLUT1 has been shown to be overexpressed in macrophages but this has not been 
compared to myocytes22. Alternatively, fasting may have reduced expression in the 
myocytes. It would be interesting to compare the numbers of Glut1 receptors at later 
times post MI when the number of M2 macrophages are dominant over the M1’s that are 
predominantly present at 5 days post MI. The high ECV also explains the high CD68 
expression as more cellular debris would lead to more macrophages. CD68 has 
previously been shown to be increased in infarcted and remote tissue post-myocardial 
infarction23. 
Limitations of this study include that the effect of fasting may be variable as we have 
shown previously9 and the small number of animals, specifically the small number of 
animals with an IOT. With this small number of animals with IOT, it is impossible to 
determine whether the volume reduction is significant. It also means that glucose 
metabolism in the IOT could not confidently be determined.  
4.5 Conclusion 
This research suggests that inflammatory cells are affected by myocardial glucose uptake 
suppression in a canine model of myocardial infarction.   This problem may be solved by 
using different tracers that do not require glucose suppression.  
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Chapter 5  
5 Conclusions, Limitations and Future Directions 
5.1 Conclusions and Future Direction 
In this final chapter, the main objectives of this thesis will be discussed and summarised. 
Additional limitations will be outlined and future directions will be discussed. The 
overall impact of this research on the field of PET/MRI in myocardial infarction imaging 
will also be considered.  
5.2 Research Objectives 
Post-myocardial infarction, patients are at risk of adverse remodeling leading to heart 
failure, in part due to an ongoing, dysregulated pro-inflammatory response. An imaging 
method is needed to determine whether patients are at risk of or currently undergoing a 
dysregulated pro-inflammatory response in remote, peri-infarct and infarcted tissue. The 
objectives of this research were to a) determine that it is safe to combine gadolinium-
based contrast agents and FDG, b) evaluate whether a constant infusion could be used to 
achieve the same glucose metabolism results at baseline as a bolus injection, c) 
longitudinally examine the use of a constant infusion post-MI and d) determine the 
effects of myocardial glucose suppression on extracellular volume and glucose 
metabolism in infarcted and remote tissue.  
5.3 Summary of Individual Chapters 
5.3.1 Chapter 1: Hybrid PET/MR imaging in myocardial 
inflammation post-myocardial infarction 
Chapter 1 describes the background for the following chapters. It highlights hybrid 
PET/MR imaging as an emerging imaging modality which is more than just a sum of its 
components, PET and MRI. PET and MRI can separately image many aspects of 
inflammation such as glucose metabolism (PET) and perfusion (MRI). However, hybrid 
PET/MRI may be able to further this goal through innovative combinations of these 
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modalities. One such example is using a dual constant infusion of the gadolinium-based 
MR contrast agent and the PET tracer, allowing for easier kinetic modeling and 
simultaneous measurements of glucose metabolism and extracellular volume. Combined 
reconstruction may also allow for enhanced motion correction of PET imaging, lowering 
the partial volume problems associated with it1.  
5.3.2 Chapter 2: Simultaneous measurements of myocardial 
glucose metabolism and extracellular volumes with hybrid 
PET/MRI using concurrent injections of Gd-DTPA and 
[18F]FDG 
Chapter 2 sets the groundwork for chapters 3 and 4 as well as future work. First of all, it 
had to be ensured that it is safe to combine Gd-DTPA and FDG or gadopentetic acid and 
FDG in one syringe. Both gadolinium-based contrast agents were tested to have an 
example of a linear and a cyclic chelator. There was no difference in pH, appearance or 
chromatography results between the original sample and the working sample, showing 
that there is no chemical change in the mixture and it is therefore safe to use. Once that 
was determined, the next step was to compare glucose metabolism and extracellular 
volume at baseline with different injection and suppression strategies. The different 
injection types were constant infusion only, bolus injection only and bolus injection 
followed by constant infusion. These were done once with suppression by heparin 
injection and lipid infusion and once with only fasting for glucose suppression. In all 
cases, the same amount of Gd-DTPA and FDG were administered. No significant 
differences were seen between the different injection methods, though ECV was 
significantly higher (13%) in the suppressed group than in the unsuppressed group. 
Overall, these similarities show that both bolus injection followed by a constant infusion 
and constant infusion only are good alternatives to the clinically used standard of care 
bolus injection2.  
5.3.3 Chapter 3: Tracking the progress of inflammation with 
PET/MRI in a canine model of myocardial infarction 
In chapter 3, a potential application of the constant infusion is examined. The IOT has 
been historically difficult to examine due to the extremely low blood flow. The 60 min 
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constant infusion protocol was applied here in order to evaluate if it would be superior in 
penetrating this region. Remote tissue has also been chronically understudied and was 
therefore examined as well. Eight animals were scanned before induction of a myocardial 
infarction and then again at days 3, 7, 14, 21 and 42 after the surgery with the goal of 
measuring the glucose metabolism and extracellular volumes in INOT, IOT and RT. IOT 
and INOT volume as well as cardiac function were also measured. While penetration into 
the IOT is shown, only 3 animals presented with an IOT region which limited the ability 
to assess a 60 min constant infusion. ECV was significantly elevated in the RT on days 
14 and 21, showing that there may be inflammation mediated extracellular edema/fibrosis 
within that tissue. This research also provided the first in-depth look at inflammation 
using PET/MRI over the first 6 weeks post-MI and provided some evidence of shrinkage 
of the apparent IOT volume over the course of a 60 minute constant infusion of contrast 
agent3. 
5.3.4 Chapter 4: Myocardial glucose suppression interferes with 
the detection of inflammatory cells with FDG-PET in a canine 
model of myocardial infarction 
While a 60 minute constant infusion reduced the apparent volume of IOT (maximum of 
50% reduction) seen on MRI, the effect was not large enough to eliminate partial volume 
effects on PET. In order to further reduce apparent IOT volume, a 150 minute constant 
infusion was used to penetrate the IOT. To test the effects of suppression of myocardial 
glucose uptake, 40 minutes into the constant infusion of Gd-DTPA and FDG, heparin 
was injected and a lipid infusion was started. ECV was unaffected by glucose suppression 
in RT and INOT at 5 days post-MI, which was consistent with the findings shown in 
chapter 3 at 7 days post-MI. Metabolic rate of glucose, on the other hand, was decreased 
in RT and INOT. The high ECV in the INOT (twice the volume fraction of remote tissue) 
suggests that the tissue is severely and irreversibly injured, with few or no viable 
myocytes. As such, the decrease in MRGlu in the INOT (figure 4-5) is likely an effect of 
glucose suppression primarily on macrophages. This finding highlights the need for 
tracers which do not rely on glucose suppression to image inflammation, e.g. PET tracers 
that target TSPO overexpressed in activated macrophages such as 18F-FEPPA. The 
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efficacy of 18F-FEPPA to image inflammation will have to be shown in a canine and 
human study, both of which are in progress. 
5.4 Limitations 
The major limitation of this work is the small number of animals, particularly the number 
of animals with microvascular obstruction. One of the goals of this research was to 
investigate the inflammatory response in the regions with microvascular obstruction but 
the small number of animals made this impractical. Using an animal model with larger 
infarcts and/or reperfusion injury, such as a 3-hour occlusion followed by reperfusion, 
may be more likely to cause the animal to have regions of microvascular obstruction4.  
In these studies, a linear gadolinium chelate, Gd-DTPA, was used. While these linear 
chelates have been largely discontinued due to the potential for gadolinium toxicity, their 
use should not affect results. There has been no evidence in literature that results obtained 
with linear chelates are inconsistent with cyclic chelates5.  
Histology was only conducted for one of the studies (Chapter 4) on day 5 post-MI. 
Histology at every timepoint would be ideal since it could be used to confirm the number 
of macrophages in all tissues to compare to ECV and glucose metabolism results in 
chapters 2 and 3. More histological data would also allow for additional information such 
as apoptosis to be obtained. In addition to histology, blood sampling to look for heart 
failure markers such as TNF-α or BNP would be a great addition to these studies since it 
would allow for further determination about whether the animals were moving into heart 
failure rather than only looking at the MRI results for cardiac function. 
FDG data was only analysed in two dimensions, to align with the T1 maps. However, 3D 
data is available due to the nature of PET. Analysing this data in 3D would be a better 
way to analyse this data, simply because there would be more data. It would not however, 
line up with the T1 maps and would lead to further difficulties regarding region of 
interest selection as that is best done on the T1 maps. The constant T1 values during a 
constant infusion, as shown in chapter 2, could resolve this problem since 3D T1 maps 
could be acquired during the equilibrium time of gadolinium concentration.  
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ECV was calculated with the assumed haematocrit of 0.45. It would be ideal to collect 
blood at every point at which ECV is calculated, i.e. every 10 minutes, or at least before 
the scan, during the scan but before the lipid infusion, during the lipid infusion, after the 
lipid infusion and at the end of the scan (in terms of the 150 minutes infusion).  
5.5 Future Work 
5.5.1 The role of the remote tissue 
Chapter 3 shows a significant difference in ECV in the remote tissue at days 14 and 21. 
While this likely shows damage due to inflammation, the FDG results were inconclusive. 
A further study with more animals and a focus on this region may be able to determine 
whether this is inflammation-related, especially if animals were sacrificed and tissue 
harvested for histology. For example, in a study with 12 animals with acute MI, 6 could 
be sacrificed at day 7 to obtain tissue samples from the acute inflammatory phase and the 
other 6 would go on to day 21 with imaging at days 3, 7, 14 and 21. Important stains 
would be CD68 for macrophages and neutrophils, Oil-Red O for lipid-laden macrophages 
(to examine fat infiltration)6, and Haematoxylin-Eosin for apoptosis. Some research also 
suggests that M1 and M2 macrophages could be distinguished when staining with both 
CD68 and CD163 but this is still controversial7.  
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Figure 5-1: Comparison of Ki in IOT and INOT. 
While the number of animals with IOT is too small to be certain, there is no significant 
change over time in Ki in the IOT tissue while the INOT decreases with significant 
differences from day 3 observed at days 14, 21 and 43.  
5.5.2 The role of the microvascular obstruction in left ventricular 
remodelling  
One of the main problems of PET/MR imaging is that it is difficult to penetrate the 
microvascular obstruction. Due to this, the extent of inflammation within that region is 
currently unknown. Chapter 3 showed the timeline of inflammation in the INOT but not 
the IOT. Shown in figure 5-1 are preliminary results where there is no significant change 
in IOT Ki over time. It would be interesting to see whether an increased number of 
animals with MO would show a similar trend or clarify the difference between the two 
curves. However, as discussed before, the number of animals with IOT is too small to be 
certain. Using a similar workflow to what we have used so far, but with an animal model 
that has a high chance of MO, perhaps reperfusion injury, would allow differences 
between the IOT and INOT to be brought to light. If there is indeed a difference in the 
timeline of inflammation in the IOT and INOT then it raises the question of whether the 
higher inflammation in the IOT affects inflammation in the INOT or the RT. It may be 
possible to focus treatment on the IOT or at least to assess the risk of heart failure in these 
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patients more accurately though better PET resolution, perhaps through hybrid 
reconstruction8, may be necessary. 
5.5.3 Interventions during a constant infusion 
In chapter 4, a 150 minute constant infusion was used with suppression of myocardial 
glucose uptake started 40 minutes into this infusion. This had a drastic effect on 
myocardial glucose uptake while ECV was unaffected. This principle could be expanded 
to other treatments or tracers, similar to a stress/rest scan. For example, during a 10 
minute constant infusion of 13NH3, adenosine could be injected at 5 minutes and 
differences in the slope of tracer uptake would show which areas have a perfusion defect 
during rest and stress. While it would be difficult to use this approach with a short-lived 
tracer such as NH3, it may be optimal for others such as 
18F-Flurpiridaz9 where the long 
half-life prevents stress-rest scans. It could also be expanded to a fatty acid tracer such as 
11C-palmitate10 where glucose or heparin could be injected partway into the scan. 
5.5.4 Patient Study 
In addition to the results shown in these studies, a patient study is underway. In this 
study, a total of 30 patients will be examined. The study consists of two imaging time-
points, the first at 7-14 days following acute MI and the second at three months following 
MI.  Before the first imaging session, patients are asked to follow a high fat diet plan and 
a 12-hour fast. Before imaging, a glucometer reading is taken. During the imaging 
session, patients receive perfusion imaging by 13NH3 PET with cine MRI to determine 
cardiac function. This is followed by a 60 min break. During this break, patients receive 
two doses of heparin to suppress myocardial glucose uptake in conjunction with the 
aforementioned high fat diet and fast. Once patients are back in the PET/MRI, pre-
contrast T1 and T2 maps are acquired. Then, the patients receive a combined bolus 
injection over 2 minutes of gadobutrol (Gadovist) and FDG followed by a 30 minute 
constant infusion of the same for a total dose of 0.2 mmol/kg Gadovist and 5 MBq/kg 
FDG. T1 maps are acquired in 2-chamber and 4-chamber views every 10 minutes for the 
first 40 minutes and then again between 50 and 60 minutes. PSIR images are acquired 
between 40 and 50 minutes. The follow up scan at 3 months post-MI is MRI only and 
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uses cine MRI to determine heart function and T1 maps before and after gadobutrol to 
determine extracellular volume.  
 
Figure 5-2: T1, T2, FDG and NH3 images in acute MI in patients.  
This figure shows, from left to right, the T1 map, T1 map with overlayed FDG and FDG 
alone in the top row and the T2 map, T2 overlayed with 13NH3 and 
13NH3 alone in the 
bottom row. The FDG image is taken from the last time frame, 57-60 minutes. Very high 
FDG uptake is seen within the infarct, meaning high inflammation.  
Analysis will include looking at the change in ejection fraction, end-systolic volume and 
end-diastolic volume from the first time point to the follow up time-point and determine 
if it is affected by the extent of inflammation at the acute time point. Additionally, Patlak 
modeling will be done to determine metabolic rate of glucose in infarcted and remote 
tissue and extracellular volume will also be measured in both tissues and at both time 
points. These values will then be compared with the change in cardiac function from the 
initial time-point to the follow-up. 13NH3 imaging provides the additional benefit of 
perfusion imaging. As such, the size of the perfusion defect can be compared to the size 
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of the metabolically active region determined with FDG PET and also with the size of the 
infarct region as determined by T1 mapping. Initial images are shown in figure 5-2. 
5.6 Conclusion 
This research has advanced the field of hybrid PET/MRI imaging of inflammation post-
MI in terms of imaging strategies. It is the first work to show that a constant infusion can 
be used to penetrate the microvascular obstruction and also the first to show detailed 
PET/MRI imaging over the first 6 weeks after myocardial infarction. It is also the first to 
show that myocardial glucose suppression with lipid infusion and heparin injection 
affects the metabolic rate of glucose in inflammatory cells. This highlights the need for 
tracers that do not depend on myocardial glucose suppression.  
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Appendices  
Appendix A: Copyright for Chapter 1: Hybrid PET/MR Imaging in Myocardial 
Inflammation Post-Myocardial Infarction 
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Appendix B: Animal Use approval for chapters 2, 3 and 4. 
 
 
 
 
Appendix C: Copyright for Chapter 2: Simultaneous measurements of myocardial 
glucose metabolism and extracellular volumes with hybrid PET/MRI using 
concurrent injections of Gd-DTPA and [18F]FDG 
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Appendix D: Copyright for Chapter 3: Tracking the progress of inflammation with 
PET/MRI in a canine model of myocardial infarction 
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